CN1749397A - Bi-recombinant active carrier vaccine of co-expression pig gyrate virus and foot and mouth disease virus - Google Patents
Bi-recombinant active carrier vaccine of co-expression pig gyrate virus and foot and mouth disease virus Download PDFInfo
- Publication number
- CN1749397A CN1749397A CN 200410011047 CN200410011047A CN1749397A CN 1749397 A CN1749397 A CN 1749397A CN 200410011047 CN200410011047 CN 200410011047 CN 200410011047 A CN200410011047 A CN 200410011047A CN 1749397 A CN1749397 A CN 1749397A
- Authority
- CN
- China
- Prior art keywords
- arg
- thr
- pro
- leu
- val
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 91
- 241000710198 Foot-and-mouth disease virus Species 0.000 title claims abstract description 36
- 229960005486 vaccine Drugs 0.000 title claims abstract description 17
- 230000004186 co-expression Effects 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 53
- 230000036039 immunity Effects 0.000 claims abstract description 7
- 241001673669 Porcine circovirus 2 Species 0.000 claims abstract 3
- 210000004027 cell Anatomy 0.000 claims description 80
- 239000013612 plasmid Substances 0.000 claims description 36
- 241000282326 Felis catus Species 0.000 claims description 18
- 230000029087 digestion Effects 0.000 claims description 18
- 102220369445 c.668T>C Human genes 0.000 claims description 17
- 239000013604 expression vector Substances 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 102220023257 rs387907546 Human genes 0.000 claims description 15
- 239000013598 vector Substances 0.000 claims description 14
- 102220023256 rs387907547 Human genes 0.000 claims description 12
- 241001465754 Metazoa Species 0.000 claims description 10
- 230000004927 fusion Effects 0.000 claims description 10
- 206010015856 Extrasystoles Diseases 0.000 claims description 9
- 102220004457 rs11567847 Human genes 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 102220369447 c.1352G>A Human genes 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 230000002068 genetic effect Effects 0.000 claims description 4
- 102220369446 c.1274G>A Human genes 0.000 claims description 3
- 102220023258 rs387907548 Human genes 0.000 claims description 3
- 101100519158 Arabidopsis thaliana PCR2 gene Proteins 0.000 claims description 2
- 241000238631 Hexapoda Species 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 230000011218 segmentation Effects 0.000 claims description 2
- 101710159752 Poly(3-hydroxyalkanoate) polymerase subunit PhaE Proteins 0.000 abstract description 22
- 101710130262 Probable Vpr-like protein Proteins 0.000 abstract description 22
- 101710172711 Structural protein Proteins 0.000 abstract description 6
- 208000015181 infectious disease Diseases 0.000 abstract description 6
- 108090000565 Capsid Proteins Proteins 0.000 abstract description 5
- 102100023321 Ceruloplasmin Human genes 0.000 abstract description 5
- 238000010171 animal model Methods 0.000 abstract description 3
- 230000001575 pathological effect Effects 0.000 abstract description 3
- 239000002243 precursor Substances 0.000 abstract description 3
- 230000007969 cellular immunity Effects 0.000 abstract description 2
- 201000006082 Chickenpox Diseases 0.000 abstract 2
- 206010046980 Varicella Diseases 0.000 abstract 2
- 210000001124 body fluid Anatomy 0.000 abstract 1
- 239000010839 body fluid Substances 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 32
- 108020004414 DNA Proteins 0.000 description 25
- 238000006243 chemical reaction Methods 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 238000002156 mixing Methods 0.000 description 21
- 239000007788 liquid Substances 0.000 description 19
- 239000006228 supernatant Substances 0.000 description 19
- 210000002966 serum Anatomy 0.000 description 18
- 238000001556 precipitation Methods 0.000 description 15
- 238000005406 washing Methods 0.000 description 13
- 239000000047 product Substances 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 239000000427 antigen Substances 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 235000015097 nutrients Nutrition 0.000 description 10
- 239000000499 gel Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 238000012216 screening Methods 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 238000013016 damping Methods 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000001962 electrophoresis Methods 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 101000833492 Homo sapiens Jouberin Proteins 0.000 description 7
- 101000651236 Homo sapiens NCK-interacting protein with SH3 domain Proteins 0.000 description 7
- 102100024407 Jouberin Human genes 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000011081 inoculation Methods 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 210000004988 splenocyte Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 241001661006 Pepper cryptic virus 2 Species 0.000 description 6
- 239000002574 poison Substances 0.000 description 6
- 231100000614 poison Toxicity 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 108010042407 Endonucleases Proteins 0.000 description 5
- 102000004533 Endonucleases Human genes 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 238000013467 fragmentation Methods 0.000 description 4
- 238000006062 fragmentation reaction Methods 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 238000010166 immunofluorescence Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 4
- 230000000050 nutritive effect Effects 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 3
- 241000178270 Canarypox virus Species 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 101150068419 ORF 1 gene Proteins 0.000 description 3
- 101150009852 ORF2 gene Proteins 0.000 description 3
- 241000709664 Picornaviridae Species 0.000 description 3
- 101100382437 Porcine circovirus 2 Cap gene Proteins 0.000 description 3
- 101000984477 Porcine circovirus 2 Capsid protein Proteins 0.000 description 3
- 101710150114 Protein rep Proteins 0.000 description 3
- 101710152114 Replication protein Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 229940023832 live vector-vaccine Drugs 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 150000002989 phenols Chemical class 0.000 description 3
- -1 polypropylene Polymers 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000008521 reorganization Effects 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 101000621943 Acholeplasma phage L2 Probable integrase/recombinase Proteins 0.000 description 2
- 101000768957 Acholeplasma phage L2 Uncharacterized 37.2 kDa protein Proteins 0.000 description 2
- 101000823746 Acidianus ambivalens Uncharacterized 17.7 kDa protein in bps2 3'region Proteins 0.000 description 2
- 101000916369 Acidianus ambivalens Uncharacterized protein in sor 5'region Proteins 0.000 description 2
- 101000769342 Acinetobacter guillouiae Uncharacterized protein in rpoN-murA intergenic region Proteins 0.000 description 2
- 101000823696 Actinobacillus pleuropneumoniae Uncharacterized glycosyltransferase in aroQ 3'region Proteins 0.000 description 2
- 101000786513 Agrobacterium tumefaciens (strain 15955) Uncharacterized protein outside the virF region Proteins 0.000 description 2
- 101000618005 Alkalihalobacillus pseudofirmus (strain ATCC BAA-2126 / JCM 17055 / OF4) Uncharacterized protein BpOF4_00885 Proteins 0.000 description 2
- 101000618348 Allochromatium vinosum (strain ATCC 17899 / DSM 180 / NBRC 103801 / NCIMB 10441 / D) Uncharacterized protein Alvin_0065 Proteins 0.000 description 2
- 102100020724 Ankyrin repeat, SAM and basic leucine zipper domain-containing protein 1 Human genes 0.000 description 2
- 101000781117 Autographa californica nuclear polyhedrosis virus Uncharacterized 12.4 kDa protein in CTL-LEF2 intergenic region Proteins 0.000 description 2
- 101000967489 Azorhizobium caulinodans (strain ATCC 43989 / DSM 5975 / JCM 20966 / LMG 6465 / NBRC 14845 / NCIMB 13405 / ORS 571) Uncharacterized protein AZC_3924 Proteins 0.000 description 2
- 101000708323 Azospirillum brasilense Uncharacterized 28.8 kDa protein in nifR3-like 5'region Proteins 0.000 description 2
- 101000770311 Azotobacter chroococcum mcd 1 Uncharacterized 19.8 kDa protein in nifW 5'region Proteins 0.000 description 2
- 101000823761 Bacillus licheniformis Uncharacterized 9.4 kDa protein in flaL 3'region Proteins 0.000 description 2
- 101000819719 Bacillus methanolicus Uncharacterized N-acetyltransferase in lysA 3'region Proteins 0.000 description 2
- 101000789586 Bacillus subtilis (strain 168) UPF0702 transmembrane protein YkjA Proteins 0.000 description 2
- 101000748761 Bacillus subtilis (strain 168) Uncharacterized MFS-type transporter YcxA Proteins 0.000 description 2
- 101000792624 Bacillus subtilis (strain 168) Uncharacterized protein YbxH Proteins 0.000 description 2
- 101000790792 Bacillus subtilis (strain 168) Uncharacterized protein YckC Proteins 0.000 description 2
- 101000765620 Bacillus subtilis (strain 168) Uncharacterized protein YlxP Proteins 0.000 description 2
- 101000819705 Bacillus subtilis (strain 168) Uncharacterized protein YlxR Proteins 0.000 description 2
- 101000916134 Bacillus subtilis (strain 168) Uncharacterized protein YqxJ Proteins 0.000 description 2
- 101000948218 Bacillus subtilis (strain 168) Uncharacterized protein YtxJ Proteins 0.000 description 2
- 101000718627 Bacillus thuringiensis subsp. kurstaki Putative RNA polymerase sigma-G factor Proteins 0.000 description 2
- 101000641200 Bombyx mori densovirus Putative non-structural protein Proteins 0.000 description 2
- 101000754349 Bordetella pertussis (strain Tohama I / ATCC BAA-589 / NCTC 13251) UPF0065 protein BP0148 Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 101000827633 Caldicellulosiruptor sp. (strain Rt8B.4) Uncharacterized 23.9 kDa protein in xynA 3'region Proteins 0.000 description 2
- 101000947628 Claviceps purpurea Uncharacterized 11.8 kDa protein Proteins 0.000 description 2
- 101000947633 Claviceps purpurea Uncharacterized 13.8 kDa protein Proteins 0.000 description 2
- 101000686796 Clostridium perfringens Replication protein Proteins 0.000 description 2
- 206010013183 Dislocation of vertebra Diseases 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 101000948901 Enterobacteria phage T4 Uncharacterized 16.0 kDa protein in segB-ipI intergenic region Proteins 0.000 description 2
- 101000805958 Equine herpesvirus 4 (strain 1942) Virion protein US10 homolog Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 101000790442 Escherichia coli Insertion element IS2 uncharacterized 11.1 kDa protein Proteins 0.000 description 2
- 101000788129 Escherichia coli Uncharacterized protein in sul1 3'region Proteins 0.000 description 2
- 101000788370 Escherichia phage P2 Uncharacterized 12.9 kDa protein in GpA 3'region Proteins 0.000 description 2
- 101000788354 Escherichia phage P2 Uncharacterized 8.2 kDa protein in gpA 5'region Proteins 0.000 description 2
- 241000700662 Fowlpox virus Species 0.000 description 2
- 101000770304 Frankia alni UPF0460 protein in nifX-nifW intergenic region Proteins 0.000 description 2
- 101000797344 Geobacillus stearothermophilus Putative tRNA (cytidine(34)-2'-O)-methyltransferase Proteins 0.000 description 2
- 101000748410 Geobacillus stearothermophilus Uncharacterized protein in fumA 3'region Proteins 0.000 description 2
- 101000787096 Geobacillus stearothermophilus Uncharacterized protein in gldA 3'region Proteins 0.000 description 2
- 101000772675 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) UPF0438 protein HI_0847 Proteins 0.000 description 2
- 101000631019 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Uncharacterized protein HI_0350 Proteins 0.000 description 2
- 101000976889 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 19.2 kDa protein in cox-rep intergenic region Proteins 0.000 description 2
- 101000768938 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 8.9 kDa protein in int-C1 intergenic region Proteins 0.000 description 2
- 101000785414 Homo sapiens Ankyrin repeat, SAM and basic leucine zipper domain-containing protein 1 Proteins 0.000 description 2
- 101000782488 Junonia coenia densovirus (isolate pBRJ/1990) Putative non-structural protein NS2 Proteins 0.000 description 2
- 101000827627 Klebsiella pneumoniae Putative low molecular weight protein-tyrosine-phosphatase Proteins 0.000 description 2
- 101000811523 Klebsiella pneumoniae Uncharacterized 55.8 kDa protein in cps region Proteins 0.000 description 2
- 101000818409 Lactococcus lactis subsp. lactis Uncharacterized HTH-type transcriptional regulator in lacX 3'region Proteins 0.000 description 2
- 101000878851 Leptolyngbya boryana Putative Fe(2+) transport protein A Proteins 0.000 description 2
- 101000758828 Methanosarcina barkeri (strain Fusaro / DSM 804) Uncharacterized protein Mbar_A1602 Proteins 0.000 description 2
- 101001122401 Middle East respiratory syndrome-related coronavirus (isolate United Kingdom/H123990006/2012) Non-structural protein ORF3 Proteins 0.000 description 2
- 101001130841 Middle East respiratory syndrome-related coronavirus (isolate United Kingdom/H123990006/2012) Non-structural protein ORF5 Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 101001055788 Mycolicibacterium smegmatis (strain ATCC 700084 / mc(2)155) Pentapeptide repeat protein MfpA Proteins 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 108091092724 Noncoding DNA Proteins 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 101000740670 Orgyia pseudotsugata multicapsid polyhedrosis virus Protein C42 Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 101000769182 Photorhabdus luminescens Uncharacterized protein in pnp 3'region Proteins 0.000 description 2
- 101000961392 Pseudescherichia vulneris Uncharacterized 29.9 kDa protein in crtE 3'region Proteins 0.000 description 2
- 101000731030 Pseudomonas oleovorans Poly(3-hydroxyalkanoate) polymerase 2 Proteins 0.000 description 2
- 101001065485 Pseudomonas putida Probable fatty acid methyltransferase Proteins 0.000 description 2
- 101000711023 Rhizobium leguminosarum bv. trifolii Uncharacterized protein in tfuA 3'region Proteins 0.000 description 2
- 101000974028 Rhizobium leguminosarum bv. viciae (strain 3841) Putative cystathionine beta-lyase Proteins 0.000 description 2
- 101000756519 Rhodobacter capsulatus (strain ATCC BAA-309 / NBRC 16581 / SB1003) Uncharacterized protein RCAP_rcc00048 Proteins 0.000 description 2
- 101000948219 Rhodococcus erythropolis Uncharacterized 11.5 kDa protein in thcD 3'region Proteins 0.000 description 2
- 101000948156 Rhodococcus erythropolis Uncharacterized 47.3 kDa protein in thcA 5'region Proteins 0.000 description 2
- 101000917565 Rhodococcus fascians Uncharacterized 33.6 kDa protein in fasciation locus Proteins 0.000 description 2
- 101000790284 Saimiriine herpesvirus 2 (strain 488) Uncharacterized 9.5 kDa protein in DHFR 3'region Proteins 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 101000936719 Streptococcus gordonii Accessory Sec system protein Asp3 Proteins 0.000 description 2
- 101000936711 Streptococcus gordonii Accessory secretory protein Asp4 Proteins 0.000 description 2
- 101000929863 Streptomyces cinnamonensis Monensin polyketide synthase putative ketoacyl reductase Proteins 0.000 description 2
- 101000788499 Streptomyces coelicolor Uncharacterized oxidoreductase in mprA 5'region Proteins 0.000 description 2
- 101000788468 Streptomyces coelicolor Uncharacterized protein in mprR 3'region Proteins 0.000 description 2
- 101001102841 Streptomyces griseus Purine nucleoside phosphorylase ORF3 Proteins 0.000 description 2
- 101000708557 Streptomyces lincolnensis Uncharacterized 17.2 kDa protein in melC2-rnhH intergenic region Proteins 0.000 description 2
- 101000845085 Streptomyces violaceoruber Granaticin polyketide synthase putative ketoacyl reductase 1 Proteins 0.000 description 2
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 2
- 101000649826 Thermotoga neapolitana Putative anti-sigma factor antagonist TM1081 homolog Proteins 0.000 description 2
- 101000711771 Thiocystis violacea Uncharacterized 76.5 kDa protein in phbC 3'region Proteins 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 101000711318 Vibrio alginolyticus Uncharacterized 11.6 kDa protein in scrR 3'region Proteins 0.000 description 2
- 101000827562 Vibrio alginolyticus Uncharacterized protein in proC 3'region Proteins 0.000 description 2
- 101000778915 Vibrio parahaemolyticus serotype O3:K6 (strain RIMD 2210633) Uncharacterized membrane protein VP2115 Proteins 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000003837 chick embryo Anatomy 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 229960004756 ethanol Drugs 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000000197 pyrolysis Methods 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 230000036413 temperature sense Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 101150097623 1B gene Proteins 0.000 description 1
- 101150019071 1C gene Proteins 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 1
- 101150033839 4 gene Proteins 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 101000818089 Acholeplasma phage L2 Uncharacterized 25.6 kDa protein Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 244000153158 Ammi visnaga Species 0.000 description 1
- 235000010585 Ammi visnaga Nutrition 0.000 description 1
- 101000770875 Autographa californica nuclear polyhedrosis virus Uncharacterized 14.2 kDa protein in PK1-LEF1 intergenic region Proteins 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 101000736909 Campylobacter jejuni Probable nucleotidyltransferase Proteins 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 102100031725 Cortactin-binding protein 2 Human genes 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108010076804 DNA Restriction Enzymes Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000748060 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 8.3 kDa protein in rep-hol intergenic region Proteins 0.000 description 1
- 101000623276 Herpetosiphon aurantiacus Uncharacterized 10.2 kDa protein in HgiBIM 5'region Proteins 0.000 description 1
- 101000623175 Herpetosiphon aurantiacus Uncharacterized 10.2 kDa protein in HgiCIIM 5'region Proteins 0.000 description 1
- 101000626850 Herpetosiphon aurantiacus Uncharacterized 10.2 kDa protein in HgiEIM 5'region Proteins 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 101000768313 Klebsiella pneumoniae Uncharacterized membrane protein in cps region Proteins 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101000804418 Methanothermobacter thermautotrophicus (strain ATCC 29096 / DSM 1053 / JCM 10044 / NBRC 100330 / Delta H) Uncharacterized protein MTH_1463 Proteins 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 101100327416 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cef-1 gene Proteins 0.000 description 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 101710087110 ORF6 protein Proteins 0.000 description 1
- 101000770870 Orgyia pseudotsugata multicapsid polyhedrosis virus Uncharacterized 37.2 kDa protein Proteins 0.000 description 1
- 108700005081 Overlapping Genes Proteins 0.000 description 1
- 240000000220 Panda oleosa Species 0.000 description 1
- 235000016496 Panda oleosa Nutrition 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001504982 Pepper cryptic virus 1 Species 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 230000010748 Photoabsorption Effects 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000202347 Porcine circovirus Species 0.000 description 1
- 101710197985 Probable protein Rev Proteins 0.000 description 1
- 102100040307 Protein FAM3B Human genes 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 101710198378 Uncharacterized 10.8 kDa protein in cox-rep intergenic region Proteins 0.000 description 1
- 101710110895 Uncharacterized 7.3 kDa protein in cox-rep intergenic region Proteins 0.000 description 1
- 101710134973 Uncharacterized 9.7 kDa protein in cox-rep intergenic region Proteins 0.000 description 1
- 101710095001 Uncharacterized protein in nifU 5'region Proteins 0.000 description 1
- 108010087302 Viral Structural Proteins Proteins 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 101150099105 alien gene Proteins 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- KLOHDWPABZXLGI-YWUHCJSESA-M ampicillin sodium Chemical compound [Na+].C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 KLOHDWPABZXLGI-YWUHCJSESA-M 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000004349 growth plate Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000010068 moulding (rubber) Methods 0.000 description 1
- 239000002362 mulch Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940023146 nucleic acid vaccine Drugs 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108010062697 pseudorabies virus glycoproteins Proteins 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention belongs to the field of biotechnology, and is especially one kind of recombinant live carrier vaccine co-expressing pig gyrate virus and foot and mouth disease virus. The present invention aims at providing two recombinant chicken pox viruses to co-express capsid protein ORF2 or its fusion protein ORF2-ORF1 of the China epidemic strain of type-II pig gyrate virus and the structural protein precursor P1 of the China epidemic strain NY00 of type-O foot and mouth disease virus, and for serving as the duplex live carrier gene engineering vaccine to prevent PCV2 and FMDV infection. The two recombinant chicken pox viruses can stimulate mouse to generate effective body fluid immunity and cell immunity, and are safe to experimental animals without any pathological phenomenon.
Description
Technical field:
The invention belongs to biological technical field, particularly relate to the live recombinant vectors vaccine of a kind of coexpression pig circular ring virus and foot and mouth disease virus.
Background technology:
Pig circular ring virus (PCV) is the animal virus of a kind of minimum of finding so far.2 type pig circular ring virus (PCV2) have pathogenic, can cause pmws (PMWS), and it is a kind of new transmissible disease.Canada broke out this disease first in 1991, and the report that all there is this disease many in the world subsequently countries and regions causes serious economy loss to pig industry.Also having in its swinery of report in Jiangsu in China Taiwan, continent, Hebei etc. has PMWS to exist.PMWS brings sizable financial loss not only for the production of pig, and publilc health is also existed potential threatens, and when speaking of xenotransplantation especially, it is pathogenic former dangerous necessary assess the new pig that does not present characteristic.Therefore strengthen the PCV2 control, develop the severe problem that practicable PCV2 vaccine and medicine are researchers.
PCV belongs to PCV-II section in classification, PCV-II section is a section of (ICTV) the 6th academic report rebaptism in the ICTV, and the common trait of this coe virus is that a kind of little, icosahedron symmetry, no cyst membrane, sub-thread are circular DNA chain composition for virus.PCV is the self-replacation mammalian virus of the present minimum of finding, is made up of capsid protein and genome.The PCV-2 genome has 11 to read frames, i.e. ORF1 ~ ORF11, and each is read frame size and differs greatly, wherein ORF1, ORF5, ORF7, ORF10,5 ' ~ 3 ' direction is identical; ORF2, ORF3, ORF4, ORF6, ORF8, ORF9, ORF11,5 ' ~ 3 ' direction is identical.These reading frames show as overlapping genes, thereby utilize the limited genetic material of PCV-II as far as possible economically, and this may be the result of natural selection in the organic evolution process.
PCV-2ORF1 has 945 bases, 314 amino acid of encoding, and PCV-2ORF2 has 702 bases, 234 amino acid of encoding.Infer that from aminoacid sequence ORF1 has 3 glycosylation sites, ORF2 and ORF5 respectively have 1 glycosylation site.Read in the frames at 11, study more deep be ORF1 and ORF2, and present research to ORF2 has become the focus that PCV2 studies.Liu Q etc. has studied the location of PCV-2ORF2 in cell with immunofluorescence method, find that 41 amino acid of ORF2 albumen n end are basic aminoacids mostly, and sequence is more conservative.Further analysis revealed the 12nd is to the 18th, and the 34th to the 41st location of amino acid domain in nuclear plays an important role.
Mahe D etc. with rhabdovirus system expression ORF1 and ORF2, though find that PCV-1ORF2 is relevant with the PCV-2ORF2 antigenicity, have only the ORF2 albumen can be by PCV2 anti-identification how.Lir Q etc. are connected to MBP-His (8)-tag gene 3 ' end with the ORF2 gene, have expressed the ORF2 fusion rotein in bacterium, this fusion rotein can with the how anti-reaction of PCV2.This shows and can distinguish PCV-1 and PCV-2 with ORF2.The inoculation of usefulness such as TruongC has the antiserum(antisera) of collecting in the PCV2 swinery to do experiment, detects (ELISA) by enzyme linked immunological absorption and identifies PCV2-ORF2 proteins encoded and Ia B cell linear epitope.Also utilize the ORF2 epitope to learn the sign that detects as PCV test pig and natural infection porcine blood serum.Also have two virus O RF1 of report proteins encoded such as Dominique Mahe that the antigen dependency is arranged, yet their ORF2 encoded protein is but resisted the identification difference of PCV2 polyclonal antibody.And PEPSCAN analyzes the overlapping fragments of ORF1, ORF2, ORF3 encoding part gene, found five with Ia determining area, one of them is positioned at ORF1, and in addition four be arranged in ORF2.And find that only some ORF2 polypeptide are immune associated epitope of difference virus type.Thereby hint uses the antigen that comes from ORF2 as diagnostic tool very big potential to be arranged.Just because of the above characteristic of ORF2, make it become the desirable antigen of diagnosis PCV on the molecular level clinically.Therefore, ORF2 also will bring into play the big effect of providing in the PCV-2 serosurvey.
Up to the present not fully aware of about this sick pathogenesis.Allan etc. think should pay attention to PCV-2 and the acting in conjunction of pig picornavirus.Because the pig picornavirus is bred in the immunocyte of pig, brings out immunosuppression probably, promote the propagation of PCV-2, perhaps the pig picornavirus has activated the susceptibility to PCV-2.
The no effective methods of treatment of this disease does not have effective vaccine both at home and abroad and can utilize.Since Wloff etc. found this new technique of naked DNA, many researchs had shown that DNA can induce protective immunological reaction to resist virus in the animal model.The plasmid DNA of also finding injection coding Pseudorabies virus glycoprotein in the past in the investigation can produce aversion response opposing lethal infection in pig muscle; Collaborative coding porcine interleukin can improve immune response, produces a kind of immunological adjuvant effect.So this research will make up nucleic acid vaccine and live vector recombinant viral genome engineering seedling,, lay the foundation for further developing efficient, safe new generation vaccine in the hope of obtaining the desirable vaccine of prevention PCV2.
The genome of foot and mouth disease virus is a single-stranded RNA, is made up of about 8500 Nucleotide, and its molecular weight is about 2.6 * 10
6Da can be divided into 5 ' end non-coding region, P1 district, P2 district, P3 district and 3 ' end non-coding region.Main structural protein of P1 district coding wherein, P2 district and P3 district coding and virus replication, translation, and complete virus particle assembles relevant Nonstructural Protein.
Structural protein P1 region nucleotide sequence total length is 2154nt, is made up of 1A, 1B, 1C and 4 gene coded sequences of 1D, and length is followed successively by 167,648,660 and 639nt, 85,218,220 and 213 the amino acid whose structural polypeptides of encoding respectively.1B, 1C and 1D are positioned at the capsid surface, are outer capsid albumen.1D encoding histone polypeptide VP1 wherein, its major part is exposed to virus surface, is the main component of decision virus antigenicity.But other three kinds of structural polypeptides also all participate in immunogenic formation.The antigen site of different serotypes virus is different, and the O C-type virus C has 5 sites: antigen site 1 is made up of 1D GH ring (1133-1157) and 200-213 amino acid whose linear epitope.This site is the topmost antigen site of FMDV, also is the key point of FMDV antigen site.
(Fowlpox Virus, FPV) expression vector system is another animal virus vector that is similar to the canary pox virus carrier to bird pox virus.FPV has the advantage identical with the canary pox virus carrier as carrier, and in addition, than the canary pox virus carrier, its genome structure is more huge, can hold bigger foreign gene and does not lose its infectivity; By the foreign protein of being expressed, in cells infected, can verily modify, as glycosylation, carboxylated etc.; The expression of exogenous gene product has good immunogenicity, can induce body to produce long-term cellular immunization and humoral immunization; Duplicate in the strict endochylema, avoided virogene to be recombined into the possibility of host cell chromosome, eliminated recombinant virus and used the potential threat of back people and animals.The host specificity of FPV makes reorganization FPV (Recombinant FPV; rFPV) only produce abortive infection behind the seeded with mammalian; but still can be in the animal of wider range correct expression alien gene; produce the correct antigen of structure picture at surface of cell membrane; thereby bring out body and produce protective immunity; and safety, effective, especially the animal to immune deficiency and immunocompromised is even more ideal carrier.So FPV not only can be used to develop the genetically engineered living vaccine of bird, and can be used as the non-replicating virus vector, development mammalian genes engineering living vaccine is used for bird animal and even human immunity in addition.Therefore, the research of FPV carrier, especially FPV are subject to people's attention day by day as the research of nonreplication vector.
Summary of the invention:
The object of the present invention is to provide the recombinant Borrel virus of two kinds of difference coexpression 2 type pig circular ring virus (PCV2) Chinese epidemic strain capsid protein ORF2 or ORF2-ORF1 (replication protein) fusion rotein and O type foot and mouth disease virus (FMDV) Chinese epidemic strain NY00 strain structural protein precursor P1, as the bigeminy genetically engineered live vector vaccine of prevention China PCV2 and FMDV infection.
The present invention sets up a new pig circular ring virus genomic library: the application PCR method increases the full gene segmentation of Chinese PCR2 epidemic strain nm2002 and is cloned in pMD18-T and the pGEM-T Easy carrier, two plasmids of pMD18T-ORF2 and pGEMT-XS have been made up, splicing and obtain the whole genome sequence of Chinese PCV2 epidemic strain nm2002;
Again gene involved in immunity is cloned into the expression vector from the Central Asia, DNA library that makes up, in host cell, gives expression to corresponding gene, as prevention or to examine protein, genetic recombinants or the recombinant immune of pmws former.
The present invention is inserted into bird pox virus expression vector pUTAL P7.5 tandem promoter downstream from the pKS-P1 carrier after with HindIII and SalI double digestion with the P1 district gene of FMDV O-NY00 strain, form intermediate carrier pUTALP1, after simultaneously the PCV2 ORF2 gene of Chinese epidemic strain PCV2nm2002 being used HincII and SmaI double digestion from carrier pMD18T-ORF2, be inserted into bird pox virus expression vector pUTALP1ATI-P7.5 combined promoter downstream, made up coexpression PCV2ORF2 and FMDV O-NY00 P1 recombinant Borrel transferring plasmid.
The gene order of pUTALP1-ORF2 is:
atg?acg?tat?cca?agg?agg?cgt?tac?cgg?aga?aga?aga?cac?cgc?ccc?cgc 48
Met?Thr?Tyr?Pro?Arg?Arg?Arg?Tyr?Arg?Arg?Arg?Arg?His?Arg?Pro?Arg
1 5 10 15
agc?cat?ctt?ggc?cag?atc?ctc?cgc?cgc?cgc?ccc?tgg?ctc?gtc?cac?ccc 96
Ser?His?Leu?Gly?Gln?Ile?Leu?Arg?Arg?Arg?Pro?Trp?Leu?Val?His?Pro
20 25 30
cgc?cac?cgt?tac?cgc?tgg?aga?agg?aaa?aat?ggc?atc?ttc?aac?acc?cgc 144
Arg?His?Arg?Tyr?Arg?Trp?Arg?Arg?Lys?Asn?Gly?Ile?Phe?Asn?Thr?Arg
35 40 45
ctc?tcc?cgc?acc?ttc?gga?tat?act?atc?aag?cga?acc?aca?gtc?aaa?acg 192
Leu?Ser?Arg?Thr?Phe?Gly?Tyr?Thr?Ile?Lys?Arg?Thr?Thr?Val?Lys?Thr
50 55 60
ccc?tcc?tgg?gcg?gtg?gac?atg?atg?aca?ttc?aat?att?aat?gac?ttt?ctt 240
Pro?Ser?Trp?Ala?Val?Asp?Met?Met?Thr?Phe?Asn?Ile?Asn?Asp?Phe?Leu
65 70 75 80
ccc?cca?gga?ggg?ggc?tca?aac?ccc?cgc?tct?gtg?ccc?ttt?gaa?tac?tac 288
Pro?Pro?Gly?Gly?Gly?Ser?Asn?Pro?Arg?Ser?Val?Pro?Phe?Glu?Tyr?Tyr
85 90 95
aga?ata?aga?aag?gtt?aag?gtt?gaa?ttc?tgg?ccc?tgc?tcc?ccg?atc?acc 336
Arg?Ile?Arg?Lys?Val?Lys?Val?Glu?Phe?Trp?Pro?Cys?Ser?Pro?I1e?Thr
100 105 110
cag?ggt?gac?agg?gga?gtg?ggc?tcc?agt?gct?gtt?att?cta?gat?gat?aac 384
Gln?Gly?Asp?Arg?Gly?Val?Gly?Ser?Ser?Ala?Val?Ile?Leu?Asp?Asp?Asn
115 120 125
ttt?gta?aca?aag?gcc?aca?gcc?ctc?acc?tat?gac?ccc?tat?gta?aac?tac 432
Phe?Val?Thr?Lys?Ala?Thr?Ala?Leu?Thr?Tyr?Asp?Pro?Tyr?Val?Asn?Tyr
130 135 140
tcc?tcc?cgc?cat?acc?ata?acc?cag?ccc?ttc?tcc?tac?cac?tcc?cgc?tac 480
Ser?Ser?Arg?His?Thr?Ile?Thr?Gln?Pro?Phe?Ser?Tyr?His?Ser?Arg?Tyr
145 150 155 160
ttt?acc?ccc?aaa?cct?gtc?cta?gat?tcc?act?att?gat?tac?ttc?caa?cca 528
Phe?Thr?Pro?Lys?Pro?Val?Leu?Asp?Ser?Thr?Ile?Asp?Tyr?Phe?Gln?Pro
165 170 175
aac?aac?aaa?aga?aat?cag?ctg?tgg?ctg?aga?cta?caa?act?gct?gga?aat 576
Ash?Asn?Lys?Arg?Asn?Gln?Leu?Trp?Leu?Arg?Leu?Gln?Thr?Ala?Gly?Asn
180 185 190
gta?gac?cac?gta?ggc?ctc?ggc?act?gcg?ttc?gaa?aac?agt?ata?tac?gac 624
Val?Asp?His?Val?Gly?Leu?Gly?Thr?Ala?Phe?Glu?Asn?Ser?Ile?Tyr?Asp
195 200 205
cag?gaa?tac?aat?atc?cgt?gta?acc?atg?tat?gta?caa?ttc?aga?gaa?ttt 672
Gln?Glu?Tyr?Asn?Ile?Arg?Val?Thr?Met?Tyr?Val?Gln?Phe?Arg?Glu?Phe
210 215 220
aat?ctt?aaa?gac?ccc?cca?ctt?aac?ccc?taa 702
Asn?Leu?Lys?Asp?Pro?Pro?Leu?Asn?Pro
225 230
The present invention is inserted into bird pox virus expression vector pUTAL P7.5 tandem promoter downstream from the pKS-P1 carrier after with HindIII and SalI double digestion with the P1 district gene of FMDV O-NY00 strain, form intermediate carrier pUTALP1, simultaneously with the middle interstitial granules pMD18T-ORF2-ORF1 of the ORF2-ORF1 fusion gene of Chinese epidemic strain PCV2nm2002 with HincII and SmaI double digestion after, be inserted into bird pox virus expression vector pUTALATI-P7.5 combined promoter downstream, make up coexpression PCV2ORF2-ORF1 and FMDV O-NY00 P1 recombinant Borrel transferring plasmid pUTALP1-ORF2-ORF1.
The gene order of pUTALPl-ORF2-ORF1 is:
atg?acg?tat?cca?agg?agg?cgt?tac?cgg?aga?aga?aga?cac?cgc?ccc?cgc 48
Met?Thr?Tyr?Pro?Arg?Arg?Arg?Tyr?Arg?Arg?Arg?Arg?His?Arg?Pro?Arg
1 5 10 15
agc?cat?ctt?ggc?cag?atc?ctc?cgc?cgc?cgc?ccc?tgg?ctc?gtc?cac?ccc 96
Ser?His?Leu?Gly?Gln?Ile?Leu?Arg?Arg?Arg?Pro?Trp?Leu?Val?His?Pro
20 25 30
cgc?cac?cgt?tac?cgc?tgg?aga?agg?aaa?aat?ggc?atc?ttc?aac?acc?cgc 144
Arg?His?Arg?Tyr?Arg?Trp?Arg?Arg?Lys?Asn?Gly?Ile?Phe?Asn?Thr?Arg
35 40 45
ctc?tcc?cgc?acc?ttc?gga?tat?act?atc?aag?cga?acc?aca?gte?aaa?acg 192
Leu?Ser?Arg?Thr?Phe?Gly?Tyr?Thr?Ile?Lys?Arg?Thr?Thr?Val?Lys?Thr
50 55 60
ccc?tcc?tgg?gcg?gtg?gac?atg?atg?aca?ttc?aat?att?aat?gac?ttt?ctt 240
Pro?Ser?Trp?Ala?Val?Asp?Met?Met?Thr?Phe?Asn?Ile?Asn?Asp?Phe?Leu
65 70 75 80
ccc?cca?gga?ggg?ggc?tca?aac?ccc?cgc?tct?gtg?ccc?ttt?gaa?tac?tac 288
Pro?Pro?Gly?Gly?Gly?Ser?Asn?Pro?Arg?Ser?Val?Pro?Phe?Glu?Tyr?Tyr
85 90 95
aga?ata?aga?aag?gtt?aag?gtt?gaa?ttc?tgg?ccc?tgc?tcc?ccg?atc?acc 336
Arg?Ile?Arg?Lys?Val?Lys?Val?Glu?Phe?Trp?Pro?Cys?Ser?Pro?Ile?Thr
100 105 110
cag?ggt?gac?agg?gga?gtg?ggc?tcc?agt?gct?gtt?att?cta?gat?gat?aac 384
Gln?Gly?Asp?Arg?Gly?Val?Gly?Ser?Ser?Ala?Val?Ile?Leu?Asp?Asp?Asn
115 120 125
ttt?gta?aca?aag?gcc?aca?gcc?ctc?acc?tat?gac?ccc?tat?gta?aac?tac 432
Phe?Val?Thr?Lys?Ala?Thr?Ala?Leu?Thr?Tyr?Asp?Pro?Tyr?Val?Asn?Tyr
130 135 140
tcc?tcc?cgc?cat?acc?ata?acc?cag?ccc?ttc?tcc?tac?cac?tcc?cgc?tac 480
Ser?Ser?Arg?His?Thr?Ile?Thr?Gln?Pro?Phe?Ser?Tyr?His?Ser?Arg?Tyr
145 150 155 160
ttt?acc?ccc?aaa?cct?gtc?cta?gat?tcc?act?att?gat?tac?ttc?caa?cca 528
Phe?Thr?Pro?Lys?Pro?Val?Leu?Asp?Ser?Thr?Ile?Asp?Tyr?Phe?Gln?Pro
165 170 175
aac?aac?aaa?aga?aat?cag?ctg?tgg?ctg?aga?cta?caa?act?gct?gga?aat 576
Asn?Asn?Lys?Arg?Asn?Gln?Leu?Trp?Leu?Arg?Leu?Gln?Thr?Ala?Gly?Asn
180 185 190
gta?gac?cac?gta?ggc?ctc?ggc?act?gcg?ttc?gaa?aac?agt?ata?tac?gac 624
Val?Asp?His?Val?Gly?Leu?Gly?Thr?Ala?Phe?Glu?Asn?Ser?Ile?Tyr?Asp
195 200 205
cag?gaa?tac?aat?atc?cgt?gta?acc?atg?tat?gta?caa?ttc?aga?gaa?ttt 672
Gln?Glu?Tyr?Asn?Ile?Arg?Val?Thr?Met?Tyr?Val?Gln?Phe?Arg?Glu?Phe
210 215 220
aat?ctt?aaa?gac?ccc?cca?ctt?aac?cct?tat?act?agt?ctg?aaa?acg?aaa 720
Asn?Leu?Lys?Asp?Pro?Pro?Leu?Asn?Pro?Tyr?Thr?Ser?Leu?Lys?Thr?Lys
225 230 235 240
gaa?gtg?cgc?tgt?aag?tat?tac?cag?cgc?act tcg?gca?gcg?gca?gca?cct 768
Glu?Val?Arg?Cys?Lys?Tyr?Tyr?Gln?Arg?Thr?Ser?Ala?Ala?Ala?Ala?Pro
245 250 255
cgg?cag?cac?ctc?agc?agc?aac?atg?ccc?agc?aag?aag?aat?gga?aga?agc 816
Arg?Gln?His?Leu?Ser?Ser?Asn?Met?Pro?Ser?Lys?Lys?Asn?Gly?Arg?Ser
260 265 270
gga?ccc?caa?ccc?cat?aaa?agg?tgg?gtg?ttc?act?ctg?aat?aat?cct?tcc 864
Gly?Pro?Gln?Pro?His?Lys?Arg?Trp?Val?Phe?Thr?Leu?Asn?Asn?Pro?Ser
275 280 285
gaa?gac?gag?cgc?aag?aaa?ata?cgg?gat?ctt?cca?ata?tcc?cta?ttt?gat 912
Glu?Asp?Glu?Arg?Lys?Lys?Ile?Arg?Asp?Leu?Pro?Ile?Ser?Leu?Phe?Asp
290 295 300
tat?ttt?att?gtt?ggc?gag?gag?ggt?aat?gag?gaa?gga?cga?aca?cct?cac 960
Tyr?Phe?Ile?Val?Gly?Glu?Glu?Gly?Asn?Glu?Glu?Gly?Arg?Thr?Pro?His
305 310 315 320
ctc?cag?ggg?ttc?gct?aat?ttt?gtg?aag?aag?cag?act?ttt?aat?aaa?gtg 1008
Leu?Gln?Gly?Phe?Ala?Asn?Phe?Val?Lys?Lys?Gln?Thr?Phe?Asn?Lys?Val
325 330 335
aag?tgg?tat?ttg?ggt?gcc?cgc?tgc?cac?atc?gag?aaa?gcg?aaa?gga?aca 1056
Lys?Trp?Tyr?Leu?Gly?Ala?Arg?Cys?His?Ile?Glu?Lys?Ala?Lys?Gly?Thr
340 345 350
gat?cag?cag?aat?aaa?gaa?tac?tgc?agt?aaa?gaa?ggc?aac?tta?ctg?atg 1104
Asp?Gln?Gln?Asn?Lys?Glu?Tyr?Cys?Ser?Lys?Glu?Gly?Asn?Leu?Leu?Met
355 360 365
gag?tgt?gga?gct?cct?aga?tct?cag?gga?caa?cgg?agt?gac?ctg?tct?act 1152
Glu?Cys?Gly?Ala?Pro?Arg?Ser?Gln?Gly?Gln?Arg?Ser?Asp?Leu?Ser?Thr
370 375 380
gct?gtg?agt?acc?ttg?ttg?gag?agc?ggg?agt?ctg?gtg?acc?gtt?gca?gag 1200
Ala?Val?Ser?Thr?Leu?Leu?Glu?Ser?Gly?Ser?Leu?Val?Thr?Val?Ala?Glu
385 390 395 400
cag?cac?cct?gta?acg?ttt?gtc?aga?aat?ttc?cgc?ggg?ctg?gct?gaa?ctt 1248
Gln?His?Pro?Val?Thr?Phe?Val?Arg?Asn?Phe?Arg?Gly?Leu?Ala?Glu?Leu
405 410 415
ttg?aaa?gtg?agc?ggg?aaa?atg?cag?aag?cgt?gat?tgg?aag?act?aat?gta 1296
Leu?Lys?Val?Ser?Gly?Lys?Met?Gln?Lys?Arg?Asp?Trp?Lys?Thr?Asn?Val
420 425 430
cac?gtc?att?gtg?ggg?cca?cct?ggg?tgt?ggt?aaa?agc?aaa?tgg?gct?gct 1344
His?Val?Ile?Val?Gly?Pro?Pro?Gly?Cys?Gly?Lys?Ser?Lys?Trp?Ala?Ala
435 440 445
aat?ttt?gca?gac?ccg?gaa?acc?aca?tac?tgg?aaa?cca?cct?aga?aac?aag 1392
Asn?Phe?Ala?Asp?Pro?Glu?Thr?Thr?Tyr?Trp?Lys?Pro?Pro?Arg?Asn?Lys
450 455 460
tgg?tgg?gat?ggt?tac?cat?ggt?gaa?gaa?gtg?gtt?gtt?att?gat?gac?ttt 1440
Trp?Trp?Asp?Gly?Tyr?His?Gly?Glu?Glu?Val?Val?Val?Ile?Asp?Asp?Phe
465 470 475 480
tat?ggc?tgg?ctg?ccc?tgg?gat?gat?cta?ctg?aga?ctg?tgt?gat?cga?tat 1488
Tyr?Gly?Trp?Leu?Pro?Trp?Asp?Asp?Leu?Leu?Arg?Leu?Cys?Asp?Arg?Tyr
485 490 495
cca?ttg?act?gta?gag?act?aaa?ggt?gga?act?gta?cct?ttt?ttg?gcc?cgc 1536
Pro?Leu?Thr?Val?Glu?Thr?Lys?Gly?Gly?Thr?Val?Pro?Phe?Leu?Ala?Arg
500 505 510
agt?att?ctg?att?acc?agc?aat?cag?acc?ccg?ttg?gaa?tgg?tac?tcc?tca 1584
Ser?Ile?Leu?Ile?Thr?Ser?Asn?Gln?Thr?Pro?Leu?Glu?Trp?Tyr?Ser?Ser
515 520 525
act?gct?gtc?cca?gct?gta?gaa?gct?ctt?tat?cgg?agg?att?act?tcc?ttg 1632
Thr?Ala?Val?Pro?Ala?Val?Glu?Ala?Leu?Tyr?Arg?Arg?Ile?Thr?Ser?Leu
530 535 540
gta?ttt?tgg?aag?aat?gct?aca?gaa?caa?tcc?acg?gag?gaa?ggg?ggc?cag 1680
Val?Phe?Trp?Lys?Asn?Ala?Thr?Glu?Gln?Ser?Thr?Glu?Glu?Gly?Gly?Gln
545 550 555 560
ttc?gtc?acc?ctt?tcc?ccc?cca?tgc?cct?gaa?ttt?cca?tat?gaa?ata?aat 1728
Phe?Val?Thr?Leu?Ser?Pro?Pro?Cys?Pro?Glu?Phe?Pro?Tyr?Glu?Ile?Asn
565 570 575
tac?tga 1734
Tyr
The associated protein of indication of the present invention can obtain expressing in the plant rhabdovirus expression vector from insect cell, also can be animal virus expression vector or the expression of other carrier for expression of eukaryon in mammalian cell.
Advantage of the present invention and positively effect:
1, the two strain recombinant Borrel virus that obtain of the present invention can be expressed PCV2 capsid protein and FMDV P1 structural protein simultaneously, and expressed proteins can be respectively and corresponding antibody generation specific reaction.
2, the two strain recombinant Borrel virus that obtain of the present invention can stimulate mouse to produce effective humoral immunization and cellular immunization.
3, the two strain recombinant Borrel virus that obtain of the present invention are safe to laboratory animal, do not have any pathological phenomena.
4, the two strain recombinant Borrel virus that obtain of the present invention have good genetic stability, and foreign gene is not lost after repeatedly going down to posterity, and can express foreign protein in non-poultry animal (as Mammals) cell.
5, goal gene used in the present invention is the P1 gene of Chinese epidemic strain O_NY00 strain FMDV and PCV2 capsid protein ORF2, replication protein ORF1 gene, thereby the recombinant Borrel virus that makes up can be used as the bigeminy genetically engineered live vector vaccine of prevention 2 type pig circular ring virus and O type foot and mouth disease virus.
Description of drawings:
Fig. 1 is that recombinant plasmid pUTALP1-ORF2 of the present invention makes up schema;
Fig. 2 is that recombinant plasmid pUTALP1-ORF2-ORF1 of the present invention makes up schema.
Embodiment:
1. the screening of being connected of the recovery of the extraction of the preparation of competent escherichia coli cell and conversion, plasmid and digestion with restriction enzyme, dna fragmentation, linear DNA fragment, recombinant plasmid and evaluation, pcr amplification reaction etc. are translated " molecular cloning experiment guide " second edition with reference to Jin Dongyan, Li Mengfeng etc., and Science Press (1992) related Sections carries out.
1.1 the preparation of competent escherichia coli cell
Under aseptic condition, picking is frozen in the bacterial classification of-70 ℃ of refrigerators, and streak inoculation is inverted for 37 ℃ and is cultivated about 16h on the LB agar plate that does not contain penbritin (Amp).The single bacterium colony of picking is inoculated into 3ml and does not contain in the antibiotic LB nutrient solution 37 ℃ of jolting overnight incubation.Aseptic absorption next day 1ml inoculum joins the 100ml that is preheated to 37 ℃ and does not contain in the LB nutrient solution of Amp, and 37 ℃ of violent joltings (200r/min) are cultivated.Be cultured to OD
600=0.4~0.5 (after about 2.5~3h), ice bath 15min makes culture be cooled to 0 ℃.Under aseptic condition, (notice that below operation all needs strict aseptic and carry out in ice-water bath), inoculum transferred in the 50ml polypropylene centrifuge tube of 2 aseptic and ice precoolings that centrifugal (4000r/min) 10min abandons supernatant under 4 ℃ of conditions; Reclaim bacterial precipitation, every pipe adds the 75mmol/LCaCl of 10ml ice precooling
2, the resuspended precipitation of 10mmol/L TrisCl (pH6.5) solution, ice bath 10min, 4 ℃ of centrifugal 10min of 4000r/min thoroughly abandon supernatant; The cold CaCl of every effective 2ml ice bath
2Preserve liquid [75mmol/L CaCl
2, 10mmol/L TrisCl pH6.5,15% (v/v) glycerine] bacterial sediment is hanged.Resuspended good competent cell is sub-packed in the aseptic Eppendorf tube, and every pipe 100l puts-70 ℃ of Ultralow Temperature Freezers or frozen standby in liquid nitrogen.
1.2 the connection of PCR product
(pMD18-T, pGEM-T Easy T carrier are connected, and (pGEM-Teasy Vector Kit, Promega company) illustrates and operate according to test kit with the T carrier with the PCR product.T carrier (30ng/l) 2l, T4 ligase enzyme 1l, it is an amount of and add water and mend to 10l to reclaim dna fragmentation, in 4 ℃ of reaction 14~16h.
1.3 transform
In frozen water, melt a competent cell, 2l is connected that product adds wherein and mixing gently, ice bath 30min, behind 42 ℃ of thermal shocking 90s, ice bath 10min adds 250l LB substratum (room temperature condition) immediately, 37 ℃ of jolting 225r/min 1h.Get 50l and 200l and be added to LB (containing 25g/ml kana or the 50g/ml Amp) agar plate that scribbles a certain amount of X-Gal (50mg/ml) and IPTG (200mg/ml) in advance, evenly after the coating, treat that bacterium liquid blots after, place 37 ℃ of overnight incubation.
1.4 the extraction of plasmid
1.4.1 a small amount of of plasmid preparation (alkaline lysis)
Under aseptic condition, with the single conversion bacterium colony of aseptic toothpick picking, being inoculated in 3ml contains in the corresponding antibiotic LB liquid nutrient medium, 37 ℃ of 250r/min jolting overnight incubation, culture is changed in the Eppendorf tube of 1.5ml, the centrifugal 3min of 6000r/min is inverted in pipe on the thieving paper, inhales as much as possible and removes residual nutrient solution.The resuspended bacterial precipitation of solution I (50mmol/L glucose, 25mmol/L TrisCl pH8.0,10mmol/L EDTA) with the precooling of 100l ice.(0.2mol/L NaOH 1%SDS), puts upside down mixing for several times, adds the solution III (3mol/L KAC, 5mol/L glacial acetic acid) of 150l ice precooling, puts upside down mixing, ice bath 5min, 4 ℃ of centrifugal 10min of 12000r/min to add the new solution II of preparing of 200l.Get supernatant and add the saturated phenol of equivalent respectively, saturated phenol: chloroform: primary isoamyl alcohol (25: 24: 1), chloroform: each extracting of primary isoamyl alcohol (24: 1) once, get at last and reset and add 2 times of cold dehydrated alcohols of volume and 1/10 volume 3M NaAc, mix, place more than the 2h for 0 ℃, the centrifugal 10min of 12000r/min, abandon supernatant, to precipitate with twice of 70% cold washing with alcohol (noting precipitating not washed losing), drying at room temperature, TE (10mmol/L TrisCl pH8.0, the 1mmol/L EDTA) dissolution precipitation of RNA enzyme (10mg/ml) that contains the no DNA enzyme of final concentration 20g/ml with 20l, 37 ℃ of water-bath 30min, after agarose gel electrophoresis was identified, it was standby to put-20 ℃ of preservations.
1.4.2 a large amount of extraction and purifications of plasmid
The microbionation that will contain the purpose plasmid is in the LB of 250ml substratum (containing corresponding microbiotic), 16~18h is cultivated in 37 ℃ of 200r/min joltings, and 4 ℃ of centrifugal 10min of 4000r/min abandon supernatant, precipitation is iced STE (the 0.1mmol/L NaCl of precooling with 50ml, 10mmol/L TrisCl pH8.0,50mmol/L EDTA) resuspended precipitation, 4 ℃ of centrifugal 10min of 4000r/min, abandon supernatant, precipitation adds the new solution II of preparing of 10ml, fully mixing with the resuspended precipitation of solution I of 5ml ice precooling, the solution III that adds the precooling of 7.5ml ice, mixing gently, ice bath 10~15min, 4 ℃ of centrifugal 15min of 7000r/min, supernatant through 4 layers of filtered through gauze to 50ml in the aseptic centrifuge tube, add 0.6 times of volume Virahol, fully mixing is placed 30min in the room temperature, the centrifugal 10min of 10000r/min, abandon supernatant, precipitation is washed once drying with 70% ethanol.After adding an amount of TE (pH8.0) dissolution precipitation, add equal-volume 5mol/L LiCl, abundant mixing, ice bath is placed 10min, the centrifugal 10min of 12000r/min, get supernatant, add the abundant mixing of equivalent Virahol, the centrifugal 10min of 10000r/min, abandon supernatant, use 70% washing with alcohol, drying at room temperature, with an amount of TE (pH8.0) dissolution precipitation, the RNA enzyme (10mg/ml) that adds no DNA enzyme is to final concentration 20g/ml, 37 ℃ of water-bath 30min, add the 1.6mol/L NaCl that equal-volume contains 13% (w/v) polyglycol solution (PEG8000), fully mixing is put 4 ℃ and is spent the night, 4 ℃ of centrifugal 10min of 12000r/min, abandon supernatant, add 400l TE (pH8.0) dissolution precipitation, with the saturated phenol of equal-volume, phenol: chloroform: primary isoamyl alcohol (25: 24: 1), chloroform: each extracting of primary isoamyl alcohol (24: 1) once, add 100l NaAC, 2 times of cold dehydrated alcohols of volume, mixing postposition-20 ℃ is deposited more than the 30min 4 ℃ of centrifugal 10min of 12000r/min, abandon supernatant, precipitate with 70% cold washing with alcohol, drying at room temperature is dissolved among the TE (pH8.0), calculate plasmid DNA concentration, be stored in-20 ℃.
1.5 plasmid DNA is quantitative
With TE (pH8.0) is blank, measures nucleic acid solution optical density(OD) (OD) value of wavelength 260nm and 280nm with TZK-800Z type ultraviolet spectrophotometer.OD
260=l is equivalent to contain the about 50g/ml of plasmid, the OD of the pure product of double-stranded DNA
260/ OD
280Value is 1.8, if OD
260/ OD
280Value is starkly lower than 1.8, then has protein or phenol and pollutes, and need be further purified.
1.6 the digestion of restriction enzyme
Single enzyme endonuclease reaction is with plasmid DNA and the suitable quantity of water mixing of 1.0g, making its cumulative volume is 20l, add 2~3ul restriction enzyme and the corresponding 10 * restriction enzyme reaction damping fluid of 2l, flick tube wall mixing and centrifugal, put optimal reactive temperature water-bath 2~3h, get the 5l reaction solution and carry out the agarose gel electrophoresis inspection.To the endonuclease reaction of a large amount of plasmid DNA, corresponding expansion restriction enzyme enzyme dosage and reaction volume, the reaction solution electrophoretic examinations that takes a morsel is behind the complete degestion, in-20 ℃ of preservations, in order to further identifying or reclaim the usefulness of fragment.
Two enzyme endonuclease reactions select two kinds of activity of enzyme reaction all to carry out double digestion reaction, the same single endonuclease digestion of the concrete grammar of its reaction in 75%~100% same buffering system.If temperature or buffering system difference, then by high temperature behind the first low temperature, the order of high salt is carried out behind the first less salt.Or first after enzyme cuts, and behind phenol, the imitative extracting DNA, ethanol sedimentation carries out second endonuclease reaction again.
1.7 from pathological material of disease, extract DNA
1) will the die of illness internal organs multigelation three times of pig is got 2g inguinal lymph nodes or mesenteric lymph nodes and is fully ground, and grinds to make it become tissue homogenate.
2) 37 ℃ of water-baths are 1 hour, and homogenate places centrifuge tube.
3) 5000rpm is centrifugal 10 minutes, gets supernatant liquor, adds 300ug/mL Proteinase K and 1%SDS therein, and 56 ℃ digested 2 hours, and used phenol, chloroform extracting 2-3 time again.
4) carefully suct clearly in clean centrifuge tube, add the NaAC of 1/10 volume and the dehydrated alcohol of 2 times of volumes.
5) 12000rpm is centrifugal 15 minutes, and precipitation is dissolved in an amount of TE damping fluid, and-20 ℃ of preservations are standby.1.8PCR the PCR reaction solution is at first disposed in reaction, comprises 10 * Ex Taq Buffer (no Mg
2+), MgCl
2(25mM), Ex Taq
TMArchaeal dna polymerase, upstream primer (20pM), downstream primer (20pM) and deionized water mix by suitable component, add above-mentioned dna profiling product again.The PCR reaction conditions is: 94 ℃ of pre-sex change 5min; 94 ℃ of sex change 1min; 51 ℃ of annealing 1min; 72 ℃ are extended 1min; After 30 circulations, 72 ℃ are extended 10min again.
1.9 the electrophoresis of PCR product and recovery purifying
The PCR product is identified in 1% agarose gel electrophoresis, determines the size of purpose band with two kinds of nucleic acid molecule amount Marker (DL-2000 and λ-EcoT14 I digest).Concrete grammar is:
1 * TAE (40mmol/L Tris-acetate, 1mmol/L EDTA) damping fluid is made into the sepharose solution of desired concn, microwave oven heating makes after agarose dissolves fully, adding ethidium bromide (5mg/ml EB) to final concentration is 0.5g/ml, pour into behind the mixing in the selected as required good electrophoresis rubber moulding, gel thicknesses is (can be suitably thicker during Rapid identification) between 3~5mm, inserts the suitable comb of width, and comb is apart from the about 0.5~1mm of base plate.Treat gel solidify fully the back (about 30~45min), carefully extract comb, gel is put into the electrophoresis chamber of the electrophoretic buffer that 0.5 * TAE is housed, make electrophoretic buffer just not have glue face (about 1mm).Get then treat in right amount electrophoretic DNA sample drop on the Parafilm film with electrophoresis sample-loading buffer (0.25% tetrabromophenol sulfonphthalein of 1/6 volume, 0.25% dimethylbenzene green grass or young crops, 40% sucrose) mixing is added to biased sample in the loading slot with micro sample adding appliance, with the voltage electrophoresis of 5V/cm.When the tetrabromophenol sulfonphthalein electrophoresis to the appropriate location, observe and the record result with long-wave ultra violet lamp.
With dna fragmentation rapid extraction/recovery test kit (Vitagene company product) the purpose fragment is reclaimed purifying.Concrete operations are:
(1) under ultraviolet lamp, downcuts the sepharose that contains target DNA, exhaust gel surface liquid and chopping with paper handkerchief.Calculated for gel weight (writing down 1.5ml centrifuge tube weight in advance), this weight is as a gel volume (as 100mg=100l);
(2) according to gel strength, add sufficient quantity DE-A solution, mix the back in 75 ℃ of heating (the low melting-point agarose gel is in 45 ℃ of heating), be interrupted and mix, melt (about 6-8 minute) fully until gel piece;
(3) add the DE-B solution of 0.5 DE-A volume, mix; When separated DNA fragment during less than 400bp, adding Virahol to final concentration is 20%;
(4) mixed solution in the absorption (3) is transferred to DNA preparation pipe, the centrifugal 1min of 3600rpm.As prepare liquid residue is arranged in the pipe, suitably improving centrifugal speed, centrifugal again 1min abandons filtrate;
(5) will prepare pipe and put back centrifuge tube, and add 0.5mlW1 solution, the centrifugal 30s of 3600rpm abandons filtrate;
(6) will prepare pipe and put back centrifuge tube, and add 0.7mlW2 solution, the centrifugal 30s of 3600rpm abandons filtrate.Use the 0.7mlW2 solution washing more once with same method;
(7) will prepare pipe and place centrifuge tube, the centrifugal 1min of top speed;
(8) will prepare pipe and place clean 1.5ml centrifuge tube, and prepare the film centre at DNA and add 25l water or elutriant, room temperature leaves standstill 1min.The centrifugal 1min eluted dna of top speed.
2. the structure of recombinant expression plasmid
2.1 the structure of interstitial granules among the fusion gene ORF2-ORF1
Behind restriction enzyme SpeI, SmaI double digestion pMD18T-ORF1 plasmid, reclaim PVC2 ORF1 gene, use SpeI, SmaI double digestion pMD18T-ORF2 plasmid simultaneously after, reclaim the big fragment that contains PCV2 ORF2 gene.The latter is connected with the ORF1 gene is directed, makes up the middle interstitial granules pMD18T-ORF2ORF1 that contains fusion gene.
2.2 contain the structure of interstitial granules in the FMDV P1 gene recombination Fowlpox virus vector
To obtain the P1 gene with the pKSP1 plasmid of Spe I digestion, after flat through mending, the terminal dephosphorization, mend flat, terminal dephosphorization with the pKS linear carrier of ClaI digestion after, both connect and transform the back recombinant plasmid pKSP1 is identified that direction is positioned at the upstream to guarantee HindIII.PKSP1 obtains the P1 gene with HindIII/SalI digestion recombinant plasmid, it is connected with pUTA2L behind the pUTA2-16Lac Z that digests with same enzyme obtain recombinant plasmid pUTA2LP1.
2.3 the structure of coexpression recombinant Borrel virus carrier transferring plasmid
Use HincII and SmaI double digestion plasmid pMD18T-ORF2 and pMD18T-ORF2ORF1 respectively, reclaim ORF2 gene and ORF2ORF1 fusion gene, be connected with the pUTALP1 that cuts also dephosphorization through the SmaI enzyme respectively, make up ORF2 gene and ORF2-ORF1 fusion gene respectively with P1 coexpression recombinant Borrel virus carrier transferring plasmid pUTALP1-ORF2, pUTALP1-ORF2ORF1.
3. the screening of homologous recombination and recombinant virus, purifying
3.1 FPV poison valency is measured
The FPV that is used for homologous recombination calculates plaque forming unit (PFU) through the passage rejuvenation, and dyes identifying virus with HE.FPV is pressed 10
2 ~10
6Extension rate is inoculated in 6 * 30mm culture plate CEF individual layer of the growth of going down to posterity, and add the MEM conduct that contains 1% methylcellulose gum and 1% calf serum (FCS) and keep liquid, 37 ℃, 5%CO
2After cultivating 120h, abandon nutrient solution, PBS (pH7.2) washes 2 times, 1% formaldehyde fixed 15min under the room temperature, the tap water washing, 0.1% violet staining 5min, tap water washing, statistics virus plaque number calculate plaque forming unit contained in every milliliter of viral liquid (Plaque forming units, PFU).
PFU=(virus plaque number * extension rate)/contamination volume (ml)
3.2 homologous recombination in the body
The transferring plasmid transfectional cell adopts liposome method: the CEF 1 * 10 that inoculation is gone down to posterity in 6 * 30mm culture plate
5~ 3 * 10
5Individual/ml, when cell grows to 80% fusion, infect the FPV of 0.1MOI (Multiplicity ofinfection), 37 ℃, 5%CO
2Behind the absorption 2h, with the mixture cotransfection of transfection reagent DOTAP that at room temperature acts on 15 ~ 30min and recombinant plasmid.Promptly in 500 μ l MEM, add 8 μ lLipofectamine
TMReagent, mixing gently, other gets 500 μ l MEM and adds recombinant plasmid dna 10 μ g mixings.Then the latter is dripped in last liquid mixing gently, the greenhouse is effect 15 ~ 30min down.12 ~ 18h after the transfection changes the freshly prepared MEM that contains 2%FCS, continues to cultivate 48 ~ 72h, results virus.The malicious valency of check weighing papova.
3.3 the screening of recombinant virus and purifying
Prepare the CEF individual layer at 6 * 30mm culture plate, connecing malicious preceding 24 hours with the MEM nutritive medium cultivation that contains 40 μ g/ml BUdR (5-bromine ribodesose uridine), then by the virus of gathering in the crops after the transfection of 10MOI inoculation recombinant expression plasmid, behind the 5%CO2 absorption 2h, cultivate 120h, harvested cell with the MEM nutritive medium that contains 40 μ g/ml BUdR again.Repeat above-mentioned experiment, with harvested cell multigelation three times, in the nutritive medium of no BUdR, cultivate then, treat that pathology appears in cell after, choose the single virus plaque respectively, behind the purifying 3 times, expand poison respectively.MEM nutritive medium with no BudR is cultivated, and waits to occur to choose the single virus plaque after the cytopathy, and expands poison respectively.
4. the PCR of recombinant virus identifies
The cell sleaker scrapes cell, the centrifugal 5min of 4000rpm, collecting cell.With PBS (pH7.4) re-suspended cell, thrum repeats twice.4ul 100ug/m Proteinase K is added in the 400ul cell pyrolysis liquid (1%SDS, 10mM NaCl, 10mM EDTA, 10mM Tris-HCl pH8.0), and 56 ℃ of water-bath 24h are bright to lysate.Then with equal-volume phenol/imitative extracting, 12, the centrifugal 10min of 000rpm.Add 800ul dehydrated alcohol and 80ulNH in the supernatant liquor
4AC ,-20 ℃ are spent the night.4 ℃ 12, the centrifugal 10min of 000rpm dries the back and acts on 1 hour, electrophoresis observation for 37 ℃ with an amount of RTE.Get final product from wherein getting 1~5ul during PCR.After the PCR reaction conditions is 95 ℃ of pre-sex change 5min, by 94 ℃ of sex change 60s, 61 ℃ of annealing 60s, 72 ℃ are extended 1min totally 30 circulations, and last 72 ℃ are extended 10min.
5. the detection of expression of recombinant virus product
5.1 indirect immunofluorescence is identified recombinant virus
Get the recombinant virus of an amount of preliminary screening and purifying, be inoculated in CEF monolayer cell on the film flying, establish the contrast of FPV and cell simultaneously.37 ℃, 5%CO
22h is made in sense, adds the MEM nutrient solution that contains 2%FCS, after continuing to cultivate cell and obvious pathology occurring, takes out film flying, and PBS (pH7.2) washes once, 4% Paraformaldehyde 96 fixedly 30min-3 hour, and PBST washes.Use 3% bovine serum albumin damping fluid PBST (1*PBS again, 0.05%Tween20) behind the solution sealing 2h, with pig PCV2 positive serum (1: 300) reaction 2h, PBST washing 3 times, then with the goat-anti pig IgG of fluorescein isothiocyanate (FITC) mark (1: 100-1: 400) reaction 2h, PBST washing 3 ~ 5 times adds a glycerine damping fluid (50% glycerine/PBST) on the slide glass, the film flying that is loaded with cell is inverted on the slide glass, under fluorescent microscope, observes and take pictures.
When the indirect immunofluorescence that carries out FMDV P1 detected, one anti-ly was the anti-FMDV polyclonal antibody of rabbit, and two anti-ly are the goat anti-rabbit igg of fluorescein isothiocyanate (FITC) mark, and all the other reagent and step are the same.
5.2 SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
Purification of Recombinant virus with after the amplification is inoculated in 10ml culturing bottle 1 * 10 respectively with 10MOI
6In individual/mlCEF cell, establish FPV contrast and cell simultaneously and contrast, when obvious pathology appears in cell, abandon nutrient solution, with TEN (40mmol/L TrisCl pH7.5, the 1mmol/L EDTA of 37 ℃ of preheatings of 1ml, 150mmol/LNaCl) wash-out cell, be collected in the Eppendorf pipe, the centrifugal 5min of 3000r/min abandons supernatant, cell precipitation is washed once with PBS, add 60 μ l lysis buffer (10mmol/L TrisCl, pH7.4,1mmol/LMgCl
2, 0.5%NP40,20 μ g/ml DNase I) and cracking, ice bath 30min boils 3min, the centrifugal 5min of 5000r/min ,-20 is frozen.
Get 30 μ l cell pyrolysis liquids and equivalent 2 * sample buffer (100mmol/L TrisCl, pH6.8,4%SDS, 0.2% tetrabromophenol sulfonphthalein, 20% glycerine, adding 2.5% beta-mercaptoethanol before using) mixing, carry out the SDS-PAGE electrophoresis in 10% gel.
5.3 immunoblotting (Western blot)
Behind the SDS-PAGE protein isolate, with its electrotransfer to nitrocellulose filter.5% skimming milk or 3% bovine serum albumin damping fluid (10mmol/L TrisCl, pH7.5,150mmol/L NaCl, 0.05%Tween20) 37 ℃ of sealing 2h, lavation buffer solution (10mmol/L TrisCl pH7.5,150mmol/L NaCl, 0.05%Tween20) washing is 3 times, each 5 ~ 10min, 2 type pig circular ring virus positive serums are with on sealing damping fluid dilution (1: 20) mulch film, 2h is made in the room temperature sense, washs 3 ~ 5 times, and 2h is made in goat-anti pig IgG (1: 300) the room temperature sense of horseradish peroxidase-labeled, after washing 3 ~ 5 times, each 5 ~ 10min is with 10mlDAB damping fluid (dissolving 6mg diaminobenzidine (DAB) in the 10mM of 9ml Tris.HCl (pH7.6) solution, the NiCl of adding 1ml0.3% (w/v)
2/ CoCl
2, to remove the throw out that may form, add 15l 30%H with Whatmanl filter paper filtering substrate solution
2O
2), use immediately behind the mixing.Washed film is moved in the shallow pallet, press 0.1ml/cm
2Add DAB substrate reactions liquid, shake gently in room temperature and carry out the incubation colour developing.Develop the color and move to nitrocellulose filter in the distilled water after 5~20 minutes or use the vitriol oil, color development stopping, observations.
When the Western blot that carries out FMDV P1 detected, one anti-ly was the anti-FMDV polyclonal antibody of rabbit, and two anti-ly are the goat anti-rabbit igg of horseradish peroxidase-labeled, and all the other reagent and step are the same.
6. the stability of expression of recombinant virus foreign protein
With the recombinant virus that obtains, passed for 10 generations continuously with the CEF cell, respectively with the 5th and the 10th generation recombinant virus with the CEF cell of the amount of 10MOI inoculation isodose, the total protein of cell of results is made SDS-PAGE and Western blot analyzes, the proteic relative expression quantity of testing goal.
7. the detected result of expression of recombinant virus product
Behind the recombinant Borrel virus vPUTAL-P1-ORF2 and vPUTAL-ORF2ORF1-P1 inoculated into chick embryo inoblast that screening obtains, locate, all can be observed special yellow-green fluorescence, illustrate that expression product is special at the cytoplasm of cells infected and cytolemma etc.; Analyze through Western blot: the cell culture analysis of reorganization poison inoculation, having occurred to be the special band of 79kD with the size of foot-and-mouth disease virus resistant antibodies, has proved that P1 albumen has obtained expression in chick embryo fibroblast; The cell culture analysis of reorganization poison inoculation, occurred can with the resisting porcine circovirus specific bands (about 25kD, 65kD) of anti-different sizes that combine how.8. the immunogenicity research of recombinant virus
8.1 recombinant virus immune mouse
Recombinant virus inoculation CEF monolayer cell is cultivated 40h, collects cells infected.4 ℃ of 3000r/min are from 10min, cell precipitation (the nutrient solution supernatant is stand-by) is suspended in 10mmol/L TrisCl (pH8.0) solution, in ultrasonic disruption on ice 4 * 15 seconds, with 4 ℃ of centrifugal 10min of 3000r/min of this suspension, get supernatant and measure viral PFU, the titre of adjusting virus makes it reach 107PFU/100ul.
36 of BALB/c female mices, body weight 18~20g divides 3 groups at random, takes injection system under the sufficient lift, injects recombinant Borrel virus vUTAL-P1-ORF2 and vUTAL-P1-ORF2ORF1 respectively and does not contain each 0.1ml of the wild poison of FPV of any foreign gene.The all immunity three times of above-mentioned each group, 20 days at interval, to pluck eyeball in the 10th day after the last immunity to get blood, the cervical vertebra dislocation is put to death, and the blood coagulation separation of serum detects the antigenic IgG antibody of anti-PCV2 for ELISA.Aseptic quantity of getting its spleen with flow cytometry analysis t lymphocyte subset class.
8.2 the detection of spleen amynologic index
8.2.1 spleen list lymphocyte suspension preparation
Mouse is put to death in the cervical vertebra dislocation, and aseptic condition takes out spleen down, places the plate that fills the PBS substratum, grinds with slide, and 200 order nylon net filters are made single cell suspension, 1500r/min, and centrifugal 5min abandons supernatant.With the centrifugal cell twice of washing of Hanks liquid, be resuspended in the RPMI RPMI-1640 that contains 10%NBS, counting transfers to 2 * 10
7Individual/ml is standby.
8.2.2 the detection of spleen t lymphocyte subset class quantity
Extracting spleen cell suspension 0.1ml adds 5ml PBS, 1500r/min, and centrifugal 10min washes cell twice, adds fluorescent mark rat anti-mouse CD in 0.5ml PBS cell suspending liquid respectively
4+And CD
8+Monoclonal antibody (this antibody dilutes by 1: 10 with PBS) 4 warm lucifuges are placed 30min, add 5ml PBS again and wash once, and the centrifugal 10min of 1500r/min will manage floor cells and suspend with 200 μ l PBS, treat that the upflowing cell instrument detects.FACS detects 10000 cells, and the gained data are carried out statistical procedures.
8.2.3 splenocyte Specific CTL Cells cytotoxic activity detects
The preparation of target cell at first makes up plasmid pDISPLAY-P1.Foot and mouth disease virus P1 gene fragment is inserted into the multiple clone site in plasmid pDISPLAY promotor CMV downstream, and construction recombination plasmid pDISPLAY-P1 is used for the preparation of target cell.This plasmid 5g and liposome 8l are softly mixed back transfection P815 cell to be cultivated.
The determining of G418 concentration cultivated 3 days with transfection P815 cell in the RPMI-1640 that contains 10% foetal calf serum after, the dilution G418 of difference is joined the nutrient solution screening of pressurizeing, the growth conditions of observation of cell obtains suitable G418 interpolation concentration.
Change cultivations of going down to posterity of cell after the pressurization screening transfection that the goal gene plasmid cell is arranged, and in its nutrient solution, add the G418 that determines suitable concn, continue cultivation.After the repeated multiple times pressurization screening, can normal growth up to cell, and cell reaches the quantity that is enough to as target cell and irritation cell.If temporarily need not, can in liquid nitrogen, store standby.
The preparation of irritation cell adjusts to 1 * 10 after using the target cell effect 4h of mitomycin (80 μ g/ml) to above-mentioned preparation
6Individual/ml, standby.
Spleen, grinding, filtration are catched and killed, take a blood sample, got to the preparation of splenocyte with mouse, with the washing of Hank ' s liquid, abandons supernatant for the last time, again with the RPMI-1640 (IL-2, the 2 μ g/ml that contain 10% calf serum; Con A, 20ng/ml) the resuspended splenocyte of 1ml, upper plate is cultivated after 1 day for 37 ℃, adds irritation cell effect 24~48h by 10: 1, adjusts spleens cell number to 1 * 10 again
7Individual/ml (note: must with irritation cell and the abundant mixing of splenocyte) continues to cultivate 4-5 days.
CTL is active to be detected
1) effector cell's numeration counts the effector cell in each sample panel, draws cell count at last and reaches 1 * 10
6Individual/ml.
2) numeration of target cell will count through the target cell of G418 pressurization screening, calculates cell quantity.
3) all with after the Hank ' s liquid washing once, the RPMI-1640 of using 5% calf serum for the last time is suspension cell again with two kinds of cells in the processing of splenocyte and target cell.
4) upper plate will be through the effector cell (4 * 10 of above-mentioned processing
6Individual cell/ml) and target cell add respectively in the 96 porocyte growth plate, and each sample is established 8 holes, and wherein 4 holes add target cell, and by the effector cell: target cell was respectively 100: 1 and 50: 1.Experiment test hole and control wells are set, and concrete grammar sees the following form.
5) the CTL killing activity detects
(1) with above-mentioned 37 ℃, 5%CO
2At least after cultivating 4h in the incubator, splenocyte is fully contacted with target cell.
(2) 45min before to be detected adds 10l lysate (10 *) in the target cell hole of containing 100l, target cell serum lactic dehydrogenase in contrast (Lactate dehydrogenase, LDH) calculate by maximum releasing value.(noting:, can add lysate 4l again) if the target cell cracking is incomplete
(3) wait to act on complete back (after being 4h), the centrifugal 4min of 250g.
(4) carefully from each hole of 96 orifice plates, shift out 50l liquid with pipettor, the respective aperture interior (noting the sample order) that adds an other elisa plate respectively, adding the substrate mixture 50l effect 30min that disposes with substrate buffer solution in advance again (notes: place rapidly after substrate and substrate mixture use up in-20 ℃ of refrigerators, must not be positioned over for a long time under 37 ℃ of conditions; In the two mechanism, must use shadings such as platinum paper).
(5) behind the effect 30min, add sulfuric acid stop buffer 50l, on microplate reader, detect behind the thorough mixing.
(6) according to the killing activity that records every group of splenocyte of data computation:
8.3 anti-PCV2 antibody in the ELISA kit measurement immune serum
Envelope antigen in the ELISA test kit is the ORF2 capsid protein of baculovirus expression, and two anti-are the goat anti-mouse igg antibody of horseradish peroxidase-labeled.
In the porous plate of " U " type, the tested serum pref of each part is become 2 parts of 50l, the serum dilution of twice serial dilution, initial titer is 1: 4, adds corresponding one and resist in each hole, hatches 1h at 37 ℃, the extent of dilution of serum rises to 1: 64 always;
With PBS liquid elisa plate is washed 5 times;
Every hole adds two resistive connection compounds of goat-anti mouse immuning ball protein horseradish peroxidase, place the rotation oscillator on 37 ℃ hatch 1h, wash plate;
Every hole of developing the color adds 50l and contains 0.05%H
2O
2Benzidine solution (30%W/V);
Stop with 50l 1.25M sulphuric acid soln termination reaction 15min.
Be determined at enzyme linked immunological instrument 620nm and measure each hole OD value.
The contrast contrast is made up of following: for the antigen of each use, with 4~8 holes, increase serum does not only add the antigen of 50l with PBS (containing 0.05%Tween-20 and phenol red indicator) dilution, corresponding mouse resisting anteserum, 2 times of serial dilutions, each extent of dilution 2 hole; Negative mice serum, 2 times of serial dilutions, each extent of dilution 2 hole.
The result judges that antibody titers can reach with 50% final extent of dilution of the virus control hole photoabsorption mean value of no tested serum with tested serum and represents.Titre is positive above 1: 40, and titre should use virus neutralization experiment heavily to examine near 1: 40 o'clock.
9. recombinant virus is in the immunology research of body animal pig
Immunology and detection method with mouse.
Detected result:
Two strain recombinant Borrel virus vPUTAL-ORF2-P1 that obtain and vPUTAL-ORF2ORF1-P1 extract the laggard performing PCR amplification of genome, all must expect the purpose fragment of size.Indirect immunofluorescence assay and Westernblot detect and are positive findings, illustrate that the recombinant Borrel virus of structure can be expressed foot and mouth disease virus structural protein precursor P1 and pig circular ring virus 2 virus capsid protein and replication protein respectively.Two strain recombinant Borrel virus all can be expressed in non-poultry animal cell, and recombinant virus has good genetic stability.With carrying out the mouse immune experiment after a large amount of amplifications of recombinant Borrel virus, can in immune serum, detect the antibody of anti-FMDV structural protein and PCV2 capsid protein, show that recombinant virus stimulates the mouse body to produce specific humoral immunity.The detection and the CTL fragmentation test result of immune mouse splenic t-cell subclass quantity show that all mouse has produced specific cellular immunity.Recombinant Borrel virus is carried out the pig immunization experiment, obtained same conclusion.
Result of study shows that two strain recombinant Borrel virus are a kind of safe and effective genetically engineered live vector vaccines, and having exploitation becomes the good prospect that is used for the preventative and therapeutic vaccine of pmws and foot and mouth disease.
<210>1
<211>702
<212>DNA
<213>virus
<220〉2 type Chinese epidemic strain PCV-ORF2 sequences
<221>gene
<222>(1)..(702)
<400>1
atg?acg?tat?cca?agg?agg?cgt?tac?cgg?aga?aga?aga?cac?cgc?ccc?cgc 48
Met?Thr?Tyr?Pro?Arg?Arg?Arg?Tyr?Arg?Arg?Arg?Arg?His?Arg?Pro?Arg
1 5 10 15
agc?cat?ctt?ggc?cag?atc?ctc?cgc?cgc?cgc?ccc?tgg?ctc?gtc?cac?ccc 96
Ser?His?Leu?Gly?Gln?Ile?Leu?Arg?Arg?Arg?Pro?Trp?Leu?Val?His?Pro
20 25 30
cgc?cac?cgt?tac?cgc?tgg?aga?agg?aaa?aat?ggc?atc?ttc?aac?acc?cgc 144
Arg?His?Arg?Tyr?Arg?Trp?Arg?Arg?Lys?Asn?Gly?Ile?Phe?Asn?Thr?Arg
35 40 45
ctc?tcc?cgc?acc?ttc?gga?tat?act?atc?aag?cga?acc?aca?gtc?aaa?acg 192
Leu?Ser?Arg?Thr?Phe?Gly?Tyr?Thr?Ile?Lys?Arg?Thr?Thr?Val?Lys?Thr
50 55 60
ccc?tcc?tgg?gcg?gtg?gac?atg?atg?aca?ttc?aat?att?aat?gac?ttt?ctt 240
Pro?Ser?Trp?Ala?Val?Asp?Met?Met?Thr?Phe?Asn?Ile?Asn?Asp?Phe?Leu
65 70 75 80
ccc?cca?gga?ggg?ggc?tca?aac?ccc?cgc?tct?gtg?ccc?ttt?gaa?tac?tac 288
Pro?Pro?Gly?Gly?Gly?Ser?Asn?Pro?Arg?Ser?Val?Pro?Phe?Glu?Tyr?Tyr
85 90 95
aga?ata?aga?aag?gtt?aag?gtt?gaa?ttc?tgg?ccc?tgc?tcc?ccg?atc?acc 336
Arg?Ile?Arg?Lys?Val?Lys?Val?Glu?Phe?Trp?Pro?Cys?Ser?Pro?Ile?Thr
100 105 110
cag?ggt?gac?agg?gga?gtg?ggc?tcc?agt?gct?gtt?att?cta?gat?gat?aac 384
Gln?Gly?Asp?Arg?Gly?Val?Gly?Ser?Ser?Ala?Val?Ile?Leu?Asp?Asp?Asn
115 120 125
ttt?gta?aca?aag?gcc?aca?gcc?ctc?acc?tat?gac?ccc?tat?gta?aac?tac 432
Phe?Val?Thr?Lys?Ala?Thr?Ala?Leu?Thr?Tyr?Asp?Pro?Tyr?Val?Asn?Tyr
130 135 140
tcc?tcc?cgc?cat?acc?ata?acc?cag?ccc?ttc?tcc?tac?cac?tcc?cgc?tac 480
Ser?Ser?Arg?His?Thr?Ile?Thr?Gln?Pro?Phe?Ser?Tyr?His?Ser?Arg?Tyr
145 150 155 160
ttt?acc?ccc?aaa?cct?gtc?cta?gat?tcc?act?att?gat?tac?ttc?caa?cca 528
Phe?Thr?Pro?Lys?Pro?Val?Leu?Asp?Ser?Thr?Ile?Asp?Tyr?Phe?Gln?Pro
165 170 175
aac?aac?aaa?aga?aat?cag?ctg?tgg?ctg?aga?cta?caa?act?gct?gga?aat 576
Asn?Asn?Lys?Arg?Asn?Gln?Leu?Trp?Leu?Arg?Leu?Gln?Thr?Ala?Gly?Asn
180 185 190
gta?gac?cac?gta?ggc?ctc?ggc?act?gcg?ttc?gaa?aac?agt?ata?tac?gac 624
Val?Asp?His?Val?Gly?Leu?Gly?Thr?Ala?Phe?Glu?Ash?Ser?Ile?Tyr?Asp
195 200 205
cag?gaa?tac?aat?atc?cgt?gta?acc?atg?tat?gta?caa?ttc?aga?gaa?ttt 672
Gln?Glu?Tyr?Asn?Ile?Arg?Val?Thr?Met?Tyr?Val?Gln?Phe?Arg?Glu?Phe
210 215 220
aat?ctt?aaa?gac?ccc?cca?ctt?aac?ccc?taa 702
Asn?Leu?Lys?Asp?Pro?Pro?Leu?Asn?Pro
225 230
<210>2
<211>1734
<212>DNA
<213>virus
<220〉2 type Chinese epidemic strain PCV-ORF1+ORF2 sequences
<221>gene
<222>(1)..(1734)
<400>2
atg?acg?tat?cca?agg?agg?cgt?tac?cgg?aga?aga?aga?cac?cgc?ccc?cgc 48
Met?Thr?Tyr?Pro?Arg?Arg?Arg?Tyr?Arg?Arg?Arg?Arg?His?Arg?Pro?Arg
1 5 10 15
agc?cat?ctt?ggc?cag?atc?ctc?cgc?cgc?cgc?ccc?tgg?ctc?gtc?cac?ccc 96
Ser?His?Leu?Gly?Gln?Ile?Leu?Arg?Arg?Arg?Pro?Trp?Leu?Val?His?Pro
20 25 30
cgc?cac?cgt?tac?cgc?tgg?aga?agg?aaa?aat?ggc?atc?ttc?aac?acc?cgc 144
Arg?His?Arg?Tyr?Arg?Trp?Arg?Arg?Lys?Asn?Gly?Ile?Phe?Asn?Thr?Arg
35 40 45
ctc?tcc?cgc?acc?ttc?gga?tat?act?atc?aag?cga?acc?aca?gtc?aaa?acg 192
Leu?Ser?Arg?Thr?Phe?Gly?Tyr?Thr?Ile?Lys?Arg?Thr?Thr?Val?Lys?Thr
50 55 60
ccc?tcc?tgg?gcg?gtg?gac?atg?atg?aca?ttc?aat?att?aat?gac?ttt?ctt 240
Pro?Ser?Trp?Ala?Val?Asp?Met?Met?Thr?Phe?Asn?Ile?Asn?Asp?Phe?Leu
65 70 75 80
ccc?cca?gga?ggg?ggc?tca?aac?ccc?cgc?tct?gtg?ccc?ttt?gaa?tac?tac 288
Pro?Pro?Gly?Gly?Gly?Ser?Asn?Pro?Arg?Ser?Val?Pro?Phe?Glu?Tyr?Tyr
85 90 95
aga?ata?aga?aag?gtt?aag?gtt?gaa?ttc?tgg?ccc?tgc?tcc?ccg?atc?acc 336
Arg?Ile?Arg?Lys?Val?Lys?Val?Glu?Phe?Trp?Pro?Cys?Ser?Pro?Ile?Thr
100 105 110
cag?ggt?gac?agg?gga?gtg?ggc?tcc?agt?gct?gtt?att?cta?gat?gat?aac 384
Gln?Gly?Asp?Arg?Gly?Val?Gly?Ser?Ser?Ala?Val?Ile?Leu?Asp?Asp?Asn
115 120 125
ttt?gta?aca?aag?gcc?aca?gcc?ctc?acc?tat?gac?ccc?tat?gta?aac?tac 432
Phe?Val?Thr?Lys?Ala?Thr?Ala?Leu?Thr?Tyr?Asp?Pro?Tyr?Val?Asn?Tyr
130 135 140
tcc?tcc?cgc?cat?acc?ata?acc?cag?ccc?ttc?tcc?tac?cac?tcc?cgc?tac 480
Ser?Ser?Arg?His?Thr?Ile?Thr?Gln?Pro?Phe?Ser?Tyr?His?Ser?Arg?Tyr
145 150 155 160
ttt?acc?ccc?aaa?cct?gtc?cta?gat?tcc?act?att?gat?tac?ttc?caa?cca 528
Phe?Thr?Pro?Lys?Pro?Val?Leu?Asp?Ser?Thr?Ile?Asp?Tyr?Phe?Gln?Pro
165 170 175
aac?aac?aaa?aga?aat?cag?ctg?tgg?ctg?aga?cta?caa?act?gct?gga?aat 576
Asn?Asn?Lys?Arg?Asn?Gln?Leu?Trp?Leu?Arg?Leu?Gln?Thr?Ala?Gly?Asn
180 185 190
gta?gac?cac?gta?ggc?ctc?ggc?act?gcg?ttc?gaa?aac?agt?ata?tac?gac 624
Val?Asp?His?Val?Gly?Leu?Gly?Thr?Ala?Phe?Glu?Asn?Ser?Ile?Tyr?Asp
195 200 205
cag?gaa?tac?aat?atc?cgt?gta?acc?atg?tat?gta?caa?ttc?aga?gaa?ttt 672
Gln?Glu?Tyr?Asn?Ile?Arg?Val?Thr?Met?Tyr?Val?Gln?Phe?Arg?Glu?Phe
210 215 220
aat?ctt?aaa?gac?ccc?cca?ctt?aac?cct?tat?act?agt?ctg?aaa?acg?aaa 720
Asn?Leu?Lys?Asp?Pro?Pro?Leu?Asn?Pro?Tyr?Thr?Ser?Leu?Lys?Thr?Lys
225 230 235 240
gaa?gtg?cgc?tgt?aag?tat?tac?cag?cgc?act?tcg?gca?gcg?gca?gca?cct 768
Glu?Val?Arg?Cys?Lys?Tyr?Tyr?Gln?Arg?Thr?Ser?Ala?Ala?Ala?Ala?Pro
245 250 255
cgg?cag?cac?ctc?agc?agc?aac?atg?ccc?agc?aag?aag?aat?gga?aga?agc 816
Arg?Gln?His?Leu?Ser?Ser?Asn?Met?Pro?Ser?Lys?Lys?Asn?Gly?Arg?Ser
260 265 270
gga?ccc?caa?ccc?cat?aaa?agg?tgg?gtg?ttc?act?ctg?aat?aat?cct?tcc 864
Gly?Pro?Gln?Pro?His?Lys?Arg?Trp?Val?Phe?Thr?Leu?Asn?Asn?Pro?Ser
275 280 285
gaa?gac?gag?cgc?aag?aaa?ata?cgg?gat?ctt?cca?ata?tcc?cta?ttt?gat 912
Glu?Asp?Glu?Arg?Lys?Lys?Ile?Arg?Asp?Leu?Pro?Ile?Ser?Leu?Phe?Asp
290 295 300
tat?ttt?att?gtt?ggc?gag?gag?ggt?aat?gag?gaa?gga?cga?aca?cct?cac 960
Tyr?Phe?Ile?Val?Gly?Glu?Glu?Gly?Asn?Glu?Glu?Gly?Arg?Thr?Pro?His
305 310 315 320
ctc?cag?ggg?ttc?gct?aat?ttt?gtg?aag?aag?cag?act?ttt?aat?aaa?gtg 1008
Leu?Gln?Gly?Phe?Ala?Asn?Phe?Val?Lys?Lys?Gln?Thr?Phe?Asn?Lys?Val
325 330 335
aag?tgg?tat?ttg?ggt?gcc?cgc?tgc?cac?atc?gag?aaa?gcg?aaa?gga?aca 1056
Lys?Trp?Tyr?Leu?Gly?Ala?Arg?Cys?His?Ile?Glu?Lys?Ala?Lys?Gly?Thr
340 345 350
gat?cag?cag?aat?aaa?gaa?tac?tgc?agt?aaa?gaa?ggc?aac?tta?ctg?atg 1104
Asp?Gln?Gln?Asn?Lys?Glu?Tyr?Cys?Ser?Lys?Glu?Gly?Asn?Leu?Leu?Met
355 360 365
gag?tgt?gga?gct?cct?aga?tct?cag?gga?caa?cgg?agt?gac?ctg?tct?act 1152
Glu?Cys?Gly?Ala?Pro?Arg?Ser?Gln?Gly?Gln?Arg?Ser?Asp?Leu?Ser?Thr
370 375 380
gct?gtg?agt?acc?ttg?ttg?gag?agc?ggg?agt?ctg?gtg?acc?gtt?gca?gag 1200
Ala?Val?Ser?Thr?Leu?Leu?Glu?Ser?Gly?Ser?Leu?Val?Thr?Val?Ala?Glu
385 390 395 400
cag?cac?cct?gta?acg?ttt?gtc?aga?aat?ttc?cgc?ggg?ctg?gct?gaa?ctt 1248
Gln?His?Pro?Val?Thr?Phe?Val?Arg?Asn?Phe?Arg?Gly?Leu?Ala?Glu?Leu
405 410 415
ttg?aaa?gtg?agc?ggg?aaa?atg?cag?aag?cgt?gat?tgg?aag?act?aat?gta 1296
Leu?Lys?Val?Ser?Gly?Lys?Met?Gln?Lys?Arg?Asp?Trp?Lys?Thr?Asn?Val
420 425 430
cac?gtc?att?gtg?ggg?cca?cct?ggg?tgt?ggt?aaa?agc?aaa?tgg?gct?gct 1344
His?Val?Ile?Val?Gly?Pro?Pro?Gly?Cys?Gly?Lys?Ser?Lys?Trp?Ala?Ala
435 440 445
aat?ttt?gca?gac?ccg?gaa?acc?aca?tac?tgg?aaa?cca?cct?aga?aac?aag 1392
Asn?Phe?Ala?Asp?Pro?Glu?Thr?Thr?Tyr?Trp?Lys?Pro?Pro?Arg?Asn?Lys
450 455 460
tgg?tgg?gat?ggt?tac?cat?ggt?gaa?gaa?gtg?gtt?gtt?att?gat?gac?ttt 1440
Trp?Trp?Asp?Gly?Tyr?His?Gly?Glu?Glu?Val?Val?Val?Ile?Asp?Asp?Phe
465 470 475 480
tat?ggc?tgg?ctg?ccc?tgg?gat?gat?cta?ctg?aga?ctg?tgt?gat?cga?tat 1488
Tyr?Gly?Trp?Leu?Pro?Trp?Asp?Asp?Leu?Leu?Arg?Leu?Cys?Asp?Arg?Tyr
485 490 495
cca?ttg?act?gta?gag?act?aaa?ggt?gga?act?gta?cct?ttt?ttg?gcc?cgc 1536
Pro?Leu?Thr?Val?Glu?Thr?Lys?Gly?Gly?Thr?Val?Pro?Phe?Leu?Ala?Arg
500 505 510
agt?att?ctg?att?acc?agc?aat?cag?acc?ccg?ttg?gaa?tgg?tac?tcc?tca 1584
Ser?Ile?Leu?Ile?Thr?Ser?Asn?Gln?Thr?Pro?Leu?Glu?Trp?Tyr?Ser?Ser
515 520 525
act?gct?gtc?cca?gct?gta?gaa?gct?ctt?tat?cgg?agg?att?act?tcc?ttg 1632
Thr?Ala?Val?Pro?Ala?Val?Glu?Ala?Leu?Tyr?Arg?Arg?Ile?Thr?Ser?Leu
530 535 540
gta?ttt?tgg?aag?aat?gct?aca?gaa?caa?tcc?acg?gag?gaa?ggg?ggc?cag 1680
Val?Phe?Trp?Lys?Asn?Ala?Thr?Glu?Gln?Ser?Thr?Glu?Glu?Gly?Gly?Gln
545 550 555 560
ttc?gtc?acc?ctt?tcc?ccc?cca?tgc?cct?gaa?ttt?cca?tat?gaa?ata?aat 1728
Phe?Val?Thr?Leu?Ser?Pro?Pro?Cys?Pro?Glu?Phe?Pro?Tyr?Glu?Ile?Asn
565 570 575
tac?tga 1734
Tyr
Claims (6)
1, the bigeminy live recombinant vectors vaccine of a kind of coexpression pig circular ring virus and foot and mouth disease virus is characterized in that:
Set up a new pig circular ring virus genomic library: the application PCR method increases the full gene segmentation of Chinese PCR2 epidemic strain nm2002 and is cloned in pMD18-T and the pGEM-T Easy carrier, two plasmids of pMD18T-ORF2 and pGEMT-XS have been made up, splicing and obtain the whole genome sequence of Chinese PCV2 epidemic strain nm2002;
Again gene involved in immunity is cloned into the expression vector from the Central Asia, DNA library that makes up, in host cell, gives expression to corresponding gene, as prevention or to examine protein, genetic recombinants or the recombinant immune of pmws former.
2, the bigeminy live recombinant vectors vaccine of coexpression pig circular ring virus according to claim 1 and foot and mouth disease virus, it is characterized in that: the P1 district gene of FMDV O-NYOO strain is inserted into the sub-downstream of bird pox virus expression vector pUTAL P7.5 tandem promoter from the pKS-P1 carrier after with HindIII and SalI double digestion, form intermediate carrier pUTALP1, after simultaneously the PCV2ORF2 gene of Chinese epidemic strain PCV2nm2002 being used HincII and SmaI double digestion from carrier pMD18T-ORF2, be inserted into bird pox virus expression vector pUTALP1ATI-P7.5 combined promoter downstream, made up coexpression PCV2ORF2 and FMDV O-NYOOP1 recombinant Borrel transferring plasmid pUTALP1-ORF2.
3, the bigeminy live recombinant vectors vaccine of coexpression pig circular ring virus according to claim 2 and foot and mouth disease virus, its gene order is:
atg?acg?tat?cca?agg?agg?cgt?tac?cgg?aga?aga?aga?cac?cgc?ccc?cgc?48
Met?Thr?Tyr?Pro?Arg?Arg?Arg?Tyr?Arg?Arg?Arg?Arg?His?Arg?Pro?Arg
1 5 10 15
agc?cat?ctt?ggc?cag?atc?ctc?cgc?cgc?cgc?ccc?tgg?ctc?gtc?cac?ccc 96
Ser?His?Leu?Gly?Gln?Ile?Leu?Arg?Arg?Arg?Pro?Trp?Leu?Val?His?Pro
20 25 30
cgc?cac?cgt?tac?cgc?tgg?aga?agg?aaa?aat?ggc?atc?ttc?aac?acc?cgc 144
Arg?His?Arg?Tyr?Arg?Trp?Arg?Arg?Lys?Asn?Gly?Ile?Phe?Asn?Thr?Arg
35 40 45
ctc?tcc?cgc?acc?ttc?gga?tat?act?atc?aag?cga?acc?aca?gtc?aaa?acg 192
Leu?Ser?Arg?Thr?Phe?Gly?Tyr?Thr?Ile?Lys?Arg?Thr?Thr?Val?Lys?Thr
50 55 60
ccc?tcc?tgg?gcg?gtg?gac?atg?atg?aca?ttc?aat?att?aat?gac?ttt?ctt 240
Pro?Ser?Trp?Ala?Val?Asp?Met?Met?Thr?Phe?Asn?Ile?Asn?Asp?Phe?Leu
65 70 75 80
ccc?cca?gga?ggg?ggc?tca?aac?ccc?cgc?tct?gtg?ccc?ttt?gaa?tac?tac 288
Pro?Pro?Gly?Gly?Gly?Ser?Asn?Pro?Arg?Ser?Val?Pro?Phe?Glu?Tyr?Tyr
85 90 95
aga?ata?aga?aag?gtt?aag?gtt?gaa?ttc?tgg?ccc?tgc?tcc?ccg?atc?acc 336
Arg?Ile?Arg?Lys?Val?Lys?Val?Glu?Phe?Trp?Pro?Cys?Ser?Pro?Ile?Thr
100 105 110
cag?ggt?gac?agg?gga?gtg?ggc?tcc?agt?gct?gtt?att?cta?gat?gat?aac 384
Gln?Gly?Asp?Arg?Gly?Val?Gly?Ser?Ser?Ala?Val?Ile?Leu?Asp?Asp?Asn
115 120 125
ttt?gta?aca?aag?gcc?aca?gcc?ctc?acc?tat?gac?ccc?tat?gta?aac?tac 432
Phe?Val?Thr?Lys?Ala?Thr?Ala?Leu?Thr?Tyr?Asp?Pro?Tyr?Val?Asn?Tyr
130 135 140
tcc?tcc?cgc?cat?acc?ata?acc?cag?ccc?ttc?tcc?tac?cac?tcc?cgc?tac 480
Ser?Ser?Arg?His?Thr?Ile?Thr?Gln?Pro?Phe?Ser?Tyr?His?Ser?Arg?Tyr
145 150 155 160
ttt?acc?ccc?aaa?cct?gtc?cta?gat?tcc?act?att?gat?tac?ttc?caa?cca 528
Phe?Thr?Pro?Lys?Pro?Val?Leu?Asp?Ser?Thr?Ile?Asp?Tyr?Phe?Gln?Pro
165 170 175
aac?aac?aaa?aga?aat?cag?ctg?tgg?ctg?aga?cta?caa?act?gct?gga?aat 576
Asn?Asn?Lys?Arg?Asn?Gln?Leu?Trp?Leu?Arg?Leu?Gln?Thr?Ala?Gly?Asn
180 185 190
gta?gac?cac?gta?ggc?ctc?ggc?act?gcg?ttc?gaa?aac?agt?ata?tac?gac 624
Val?Asp?His?Val?Gly?Leu?Gly?Thr?Ala?Phe?Glu?Asn?Ser?Ile?Tyr?Asp
195 200 205
cag?gaa?tac?aat?atc?cgt?gta?acc?atg?tat?gta?caa?ttc?aga?gaa?ttt 672
Gln?Glu?Tyr?Asn?Ile?Arg?Val?Thr?Met?Tyr?Val?Gln?Phe?Arg?Glu?Phe
210 215 220
aat?ctt?aaa?gac?ccc?cca?ctt?aac?ccc?taa 702
Asn?Leu?Lys?Asp?Pro?Pro?Leu?Asn?Pro
225 230
4, the bigeminy live recombinant vectors vaccine of coexpression pig circular ring virus according to claim 1 and foot and mouth disease virus, it is characterized in that: the P1 district gene of FMDV O-NYOO strain is inserted into the sub-downstream of bird pox virus expression vector pUTAL P7.5 tandem promoter from the pKS-P1 carrier after with HindIII and SalI double digestion, form intermediate carrier pUTALP1, simultaneously with the middle interstitial granules pMD18T-ORF2-ORF1 of the ORF2-ORF1 fusion gene of Chinese epidemic strain PCV2 nm2002 with HincII and SmaI double digestion after, be inserted into bird pox virus expression vector pUTAL ATI-P7.5 combined promoter downstream, make up coexpression PCV2ORF2-ORF1 and FMDV O-NYOO P1 recombinant Borrel transferring plasmid pUTALP1-ORF2-ORF1.
5, the bigeminy live recombinant vectors vaccine of coexpression pig circular ring virus according to claim 4 and foot and mouth disease virus, its gene order is:
atg?acg?tat?cca?agg?agg?cgt?tac?cgg?aga?aga?aga?cac?cgc?ccc?cgc 48
Met?Thr?Tyr?Pro?Arg?Arg?Arg?Tyr?Arg?Arg?Arg?Arg?His?Arg?Pro?Arg
1 5 10 15
agc?cat?ctt?ggc?cag?atc?ctc?cgc?cgc?cgc?ccc?tgg?ctc?gtc?cac?ccc 96
Ser?His?Leu?Gly?Gln?Ile?Leu?Arg?Arg?Arg?Pro?Trp?Leu?Val?His?Pro
20 25 30
cgc?cac?cgt?tac?cgc?tgg?aga?agg?aaa?aat?ggc?atc?ttc?aac?acc?cgc 144
Arg?His?Arg?Tyr?Arg?Trp?Arg?Arg?Lys?Asn?Gly?Ile?Phe?Asn?Thr?Arg
35 40 45
ctc?tcc?cgc?acc?ttc?gga?tat?act?atc?aag?cga?acc?aca?gtc?aaa?acg 192
Leu?Ser?Arg?Thr?Phe?Gly?Tyr?Thr?Ile?Lys?Arg?Thr?Thr?Val?Lys?Thr
50 55 60
ccc?tcc?tgg?gcg?gtg?gac?atg?atg?aca?ttc?aat?att?aat?gac?ttt?ctt 240
Pro?Ser?Trp?Ala?Val?Asp?Met?Met?Thr?Phe?Asn?Ile?Asn?Asp?Phe?Leu
65 70 75 80
ccc?cca?gga?ggg?ggc?tca?aac?ccc?cgc?tct?gtg?ccc?ttt?gaa?tac?tac 288
Pro?Pro?Gly?Gly?Gly?Ser?Asn?Pro?Arg?Ser?Val?Pro?Phe?Glu?Tyr?Tyr
85 90 95
aga?ata?aga?aag?gtt?aag?gtt?gaa?ttc?tgg?ccc?tgc?tcc?ccg?atc?acc 336
Arg?Ile?Arg?Lys?Val?Lys?Val?Glu?Phe?Trp?Pro?Cys?Ser?Pro?Ile?Thr
100 105 110
cag?ggt?gac?agg?gga?gtg?ggc?tcc?agt?gct?gtt?att?cta?gat?gat?aac 384
Gln?Gly?Asp?Arg?Gly?Val?Gly?Ser?Ser?Ala?Val?Ile?Leu?Asp?Asp?Asn
115 120 125
ttt?gta?aca?aag?gcc?aca?gcc?ctc?acc?tat?gac?ccc?tat?gta?aac?tac 432
Phe?Val?Thr?Lys?Ala?Thr?Ala?Leu?Thr?Tyr?Asp?Pro?Tyr?Val?Asn?Tyr
130 135 140
tcc?tcc?cgc?cat?acc?ata?acc?cag?ccc?ttc?tcc?tac?cac?tcc?cgc?tac 480
Ser?Ser?Arg?His?Thr?Ile?Thr?Gln?Pro?Phe?Ser?Tyr?His?Ser?Arg?Tyr
145 150 155 160
ttt?acc?ccc?aaa?cct?gtc?cta?gat?tcc?act?att?gat?tac?ttc?caa?cca 528
Phe?Thr?Pro?Lys?Pro?Val?Leu?Asp?Ser?Thr?Ile?Asp?Tyr?Phe?Gln?Pro
165 170 175
aac?aac?aaa?aga?aat?cag?ctg?tgg?ctg?aga?cta?caa?act?gct?gga?aat 576
Asn?Asn?Lys?Arg?Asn?Gln?Leu?Trp?Leu?Arg?Leu?Gln?Thr?Ala?Gly?Asn
180 185 190
gta?gac?cac?gta?ggc?ctc?ggc?act?gcg?ttc?gaa?aac?agt?ata?tac?gac 624
Val?Asp?His?Val?Gly?Leu?Gly?Thr?Ala?Phe?Glu?Asn?Ser?Ile?Tyr?Asp
195 200 205
cag?gaa?tac?aat?atc?cgt?gta?acc?atg?tat?gta?caa?ttc?aga?gaa?ttt 672
Gln?Glu?Tyr?Asn?Ile?Arg?Val?Thr?Met?Tyr?Val?Gln?Phe?Arg?Glu?Phe
210 215 220
aat?ctt?aaa?gac?ccc?cca?ctt?aac?cct?tat?act?agt?ctg?aaa?acg?aaa 720
Asn?Leu?Lys?Asp?Pro?Pro?Leu?Asn?Pro?Tyr?Thr?Ser?Leu?Lys?Thr?Lys
225 230 235 240
gaa?gtg?cgc?tgt?aag?tat?tac?cag?cgc?act?tcg?gca?gcg?gca?gca?cct 768
Glu?Val?Arg?Cys?Lys?Tyr?Tyr?Gln?Arg?Thr?Ser?Ala?Ala?Ala?Ala?Pro
245 250 255
cgg?cag?cac?ctc?agc?agc?aac?atg?ccc?agc?aag?aag?aat?gga?aga?agc 816
Arg?Gln?His?Leu?Ser?Ser?Asn?Met?Pro?Ser?Lys?Lys?Asn?Gly?Arg?Ser
260 265 270
gga?ccc?caa?ccc?cat?aaa?agg?tgg?gtg?ttc?act?ctg?aat?aat?cct?tcc 864
Gly?Pro?Gln?Pro?His?Lys?Arg?Trp?Val?Phe?Thr?Leu?Asn?Asn?Pro?Ser
275 280 285
gaa?gac?gag?cgc?aag?aaa?ata?cgg?gat?ctt?cca?ata?tcc?cta?ttt?gat 912
Glu?Asp?Glu?Arg?Lys?Lys?Ile?Arg?Asp?Leu?Pro?Ile?Ser?Leu?Phe?Asp
290 295 300
tat?ttt?att?gtt?ggc?gag?gag?ggt?aat?gag?gaa?gga?cga?aca?cct?cac 960
Tyr?Phe?Ile?Val?Gly?Glu?Glu?Gly?Asn?Glu?Glu?Gly?Arg?Thr?Pro?His
305 310 315 320
ctc?cag?ggg?ttc?gct?aat?ttt?gtg?aag?aag?cag?act?ttt?aat?aaa?gtg 1008
Leu?Gln?Gly?Phe?Ala?Asn?Phe?Val?Lys?Lys?Gln?Thr?Phe?Asn?Lys?Val
325 330 335
aag?tgg?tat?ttg?ggt?gcc?cgc?tgc?cac?atc?gag?aaa?gcg?aaa?gga?aca 1056
Lys?Trp?Tyr?Leu?Gly?Ala?Arg?Cys?His?Ile?Glu?Lys?Ala?Lys?Gly?Thr
340 345 350
gat?cag?cag?aat?aaa?gaa?tac?tgc?agt?aaa?gaa?ggc?aac?tta?ctg?atg 1104
Asp?Gln?Gln?Asn?Lys?Glu?Tyr?Cys?Ser?Lys?Glu?Gly?Asn?Leu?Leu?Met
355 360 365
gag?tgt?gga?gct?cct?aga?tct?cag?gga?caa?cgg?agt?gac?ctg?tct?act 1152
Glu?Cys?Gly?Ala?Pro?Arg?Ser?Gln?Gly?Gln?Arg?Ser?Asp?Leu?Ser?Thr
370 375 380
gct?gtg?agt?acc?ttg?ttg?gag?agc?ggg?agt?ctg?gtg?acc?gtt?gca?gag 1200
Ala?Val?Ser?Thr?Leu?Leu?Glu?Ser?Gly?Ser?Leu?Val?Thr?Val?Ala?Glu
385 390 395 400
cag?cac?cct?gta?acg?ttt?gtc?aga?aat?ttc?cgc?ggg?ctg?gct?gaa?ctt 1248
Gln?His?Pro?Val?Thr?Phe?Val?Arg?Asn?Phe?Arg?Gly?Leu?Ala?Glu?Leu
405 410 415
ttg?aaa?gtg?agc?ggg?aaa?atg?cag?aag?cgt?gat?tgg?aag?act?aat?gta 1296
Leu?Lys?Val?Ser?Gly?Lys?Met?Gln?Lys?Arg?Asp?Trp?Lys?Thr?Asn?Val
420 425 430
cac?gtc?att?gtg?ggg?cca?cct?ggg?tgt?ggt?aaa?agc?aaa?tgg?gct?gct 1344
His?Val?Ile?Val?Gly?Pro?Pro?Gly?Cys?Gly?Lys?Ser?Lys?Trp?Ala?Ala
435 440 445
aat?ttt?gca?gac?ccg?gaa?acc?aca?tac?tgg?aaa?cca?cct?aga?aac?aag 1392
Asn?Phe?Ala?Asp?Pro?Glu?Thr?Thr?Tyr?Trp?Lys?Pro?Pro?Arg?Asn?Lys
450 455 460
tgg?tgg?gat?ggt?tac?cat?ggt?gaa?gaa?gtg?gtt?gtt?att?gat?gac?ttt 1440
Trp?Trp?Asp?Gly?Tyr?His?Gly?Glu?Glu?Val?Val?Val?Ile?Asp?Asp?Phe
465 470 475 480
tat?ggc?tgg?ctg?ccc?tgg?gat?gat?cta?ctg?aga?ctg?tgt?gat?cga?tat 1488
Tyr?Gly?Trp?Leu?Pro?Trp?Asp?Asp?Leu?Leu?Arg?Leu?Cys?Asp?Arg?Tyr
485 490 495
cca?ttg?act?gta?gag?act?aaa?ggt?gga?act?gta?cct?ttt?ttg?gcc?cgc 1536
Pro?Leu?Thr?Val?Glu?Thr?Lys?Gly?Gly?Thr?Val?Pro?Phe?Leu?Ala?Arg
500 505 510
agt?att?ctg?att?acc?agc?aat?cag?acc?ccg?ttg?gaa?tgg?tac?tcc?tca 1584
Ser?Ile?Leu?Ile?Thr?Ser?Asn?Gln?Thr?Pro?Leu?Glu?Trp?Tyr?Ser?Ser
515 520 525
act?gct?gtc?cca?gct?gta?gaa?gct?ctt?tat?cgg?agg?att?act?tcc?ttg 1632
Thr?Ala?Val?Pro?Ala?Val?Glu?Ala?Leu?Tyr?Arg?Arg?Ile?Thr?Ser?Leu
530 535 540
gta?ttt?tgg?aag?aat?gct?aca?gaa?caa?tcc?acg?gag?gaa?ggg?ggc?cag 1680
Val?Phe?Trp?Lys?Asn?Ala?Thr?Glu?Gln?Ser?Thr?Glu?Glu?Gly?Gly?Gln
545 550 555 560
ttc?gtc?acc?ctt?tcc?ccc?cca?tgc?cct?gaa?ttt?cca?tat?gaa?ata?aat 1728
Phe?Val?Thr?Leu?Ser?Pro?Pro?Cys?Pro?Glu?Phe?Pro?Tyr?Glu?Ile?Asn
565 570 575
tac?tga 1734
Tyr
6, the bigeminy live recombinant vectors vaccine of coexpression pig circular ring virus according to claim 1 and foot and mouth disease virus, it is characterized in that: associated protein can obtain expressing in the plant rhabdovirus expression vector from insect cell, also can be animal virus expression vector or the expression of other carrier for expression of eukaryon in mammalian cell.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410011047 CN1749397B (en) | 2004-08-18 | 2004-08-18 | Bi-recombinant active carrier vaccine of co-expression pig gyrate virus and foot and mouth disease virus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410011047 CN1749397B (en) | 2004-08-18 | 2004-08-18 | Bi-recombinant active carrier vaccine of co-expression pig gyrate virus and foot and mouth disease virus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1749397A true CN1749397A (en) | 2006-03-22 |
| CN1749397B CN1749397B (en) | 2010-12-08 |
Family
ID=36605053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410011047 Expired - Fee Related CN1749397B (en) | 2004-08-18 | 2004-08-18 | Bi-recombinant active carrier vaccine of co-expression pig gyrate virus and foot and mouth disease virus |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1749397B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101220375B (en) * | 2007-01-11 | 2011-07-27 | 华南农业大学 | Fowl pox virus double-gene expression carrier (PT7.5N) |
| CN102861327A (en) * | 2012-09-27 | 2013-01-09 | 郑州后羿制药有限公司 | Cell inactivated vaccine, egg yoke antibody and injection and freeze-dried powder containing same |
| CN103865955A (en) * | 2009-10-16 | 2014-06-18 | 佐蒂斯有限责任公司 | Infectious clones of Torque teno virus |
| CN110041409A (en) * | 2019-05-07 | 2019-07-23 | 山东省农业科学院畜牧兽医研究所 | A kind of saltant type porcine circovirus 2 type is viral and applies |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7276353B2 (en) * | 2001-12-12 | 2007-10-02 | Virginia Tech Intellectual Properties, Inc. | Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof |
-
2004
- 2004-08-18 CN CN 200410011047 patent/CN1749397B/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101220375B (en) * | 2007-01-11 | 2011-07-27 | 华南农业大学 | Fowl pox virus double-gene expression carrier (PT7.5N) |
| CN103865955A (en) * | 2009-10-16 | 2014-06-18 | 佐蒂斯有限责任公司 | Infectious clones of Torque teno virus |
| CN102861327A (en) * | 2012-09-27 | 2013-01-09 | 郑州后羿制药有限公司 | Cell inactivated vaccine, egg yoke antibody and injection and freeze-dried powder containing same |
| CN110041409A (en) * | 2019-05-07 | 2019-07-23 | 山东省农业科学院畜牧兽医研究所 | A kind of saltant type porcine circovirus 2 type is viral and applies |
| CN110041409B (en) * | 2019-05-07 | 2022-09-06 | 山东省农业科学院畜牧兽医研究所 | Mutant porcine circovirus type 2 virus and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1749397B (en) | 2010-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1195854C (en) | Porcine circovirus recombinant poxvirus vaccine | |
| CN1824774A (en) | Culturing method of auxilliary bud less tobacco after topping | |
| CN1122108C (en) | Immunogenic peptides of foot-and-mouth disease virus | |
| CN1160454C (en) | Enhanced immunogen for inactivated vaccine against Japanese encephalitis virus infection and production method thereof | |
| CN1569899A (en) | Recombinant nerve putrescence virus protein vaccine and its coding sequence and uses | |
| CN1495255A (en) | Method for obtaining non-inclusion body baculovirus | |
| CN1495262A (en) | Non-splicing variants of gp350/220 | |
| CN1749397A (en) | Bi-recombinant active carrier vaccine of co-expression pig gyrate virus and foot and mouth disease virus | |
| CN1283780C (en) | Method for constructing genetic engineering fungus of monascus with no citrinin | |
| CN1990869A (en) | Chicken infectivity bursa of Fabricius virus VP2 cDNA, its expression vector, expressed recombinant protein and application thereof | |
| CN1690223A (en) | Human papilomavirus typing gene chip detecting system | |
| CN1629188A (en) | Specific Antigen and Application of Schistosoma japonicum | |
| CN1737144A (en) | Composite multiple epitope bivalent nucleic acid vaccine construction for foot-and-mouth disease | |
| CN1899610A (en) | Pyloric spiral bacillus antigen recombinant vaccine | |
| CN1212399C (en) | Method of obtaining transgenic mountain lettuce chloroplast plant for producing foot-and-mouth disease vaccine | |
| CN101065489A (en) | Construct of swine vesicular disease virus like particle using genetic engineering and the method for manufacturing thereof | |
| CN1793172A (en) | Non-inducing expressing gene engineering strain and structural process and application thereof | |
| CN1736479A (en) | Prevention, treatment and detection of progressive atrophic rhinitis in pigs | |
| CN1258317A (en) | Process for expression of genes of dengue viruses | |
| CN1597938A (en) | Recombined rhabdovirus containing double valence insect resisting gene | |
| CN1821409A (en) | A novel fungal pathogenicity gene MgKIN17 derived from Pyrospora sp. and its application | |
| CN1193773C (en) | Cicada mycelium capsule and preparation method | |
| CN1616478A (en) | Expression and application of p27 protein | |
| CN1261593C (en) | Application of IC53 gene and its related products in preparation of drugs for diagnosis and treatment of colon cancer and a kit for diagnosis of colon cancer | |
| CN1635161A (en) | Turbot reddish body iridovirus virus polymerase chain reaction detection method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20101208 Termination date: 20130818 |